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iv 
Obesity is a problem of great public health significance, with over one-third of individuals in the 
U.S. being obese; it is also associated with an increased risk for cardiometabolic diseases. 
Abnormal cytokine secretion of pro-inflammatory (IL-6 and TNF-α) and anti-inflammatory 
(adiponectin and IL-10) cytokines is a hallmark of obesity, linking it to the development of 
insulin resistance (IR). Weight maintenance after intentional weight loss is difficult to achieve, 
and individuals often regain weight, entering into a pattern of weight cycling. Little is known on 
the associations between weight cycling, cytokines, and IR. This dissertation, comprising three 
research papers, aimed to examine these associations among non-diabetic, overweight/obese 
adults (N=66) enrolled in the Self-Monitoring And Recording using Technology (SMART) 
Trial, a 24-month clinical trial of behavioral weight loss treatment. 
The first paper examined patterns of weight loss and regain and its effect on pro- and 
anti-inflammatory cytokines from baseline to 24 months. An interaction between gender and 
percent change in weight on percent change in adiponectin over time was detected 
[b(se)=0.9(0.2), p=.0003]. There was an association with increases in IL-6 [b(se)=0.9(0.3), 
p=.001]. The second paper examined patterns of weight loss and regain and their effect on 
metabolic measures from baseline to 24 months. Weight change was positively associated with 
changes in insulin [b(se)=0.5(0.1), p≤.0001] and HOMA-IR [b(se)=0.8(0.2), p≤.0001] over time. 
Lora E. Burke, PhD, MPH 
ASSOCIATIONS BETWEEN WEIGHT LOSS AND REGAIN, CYTOKINE 
CONCENTRATION, AND INSULIN RESISTANCE AMONG 
OVERWEIGHT/OBESE ADULTS  
Erica Joy Ambeba, PhD 
University of Pittsburgh, 2013
ABSTRACT
v 
The third paper examined polymorphisms in genes encoding IL-6, TNF-α, adiponectin, and IL-
10 and their association with cytokine concentration and IR. C allele carriers in IL-10 
polymorphism rs1800896 had higher HOMA-IR compared to TT carriers [b(se)=1.0(0.4), 
p=0.02]. Variant allele carriers in IL-10 polymorphisms rs1800871 and rs1800872 had lower 
HOMA-IR compared to individuals homozygous for the wild type allele [for both 
polymorphisms: b(se)=-1.2(0.4), p=.01]. There was a significant within-group decrease in 
HOMA-IR from baseline to 24 months among individuals with the rs1800872 GG genotype but 
not for T allele carriers. 
These findings reveal weight loss to be an important tool in reducing inflammation and 
improving insulin sensitivity; however, weight regain can attenuate these improvements. 
Moreover, the association between IL-10 polymorphisms and IR suggests that cytokine genes 
play a role in metabolic outcomes.  
vi 
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1.0  DISSERTATION INTRODUCTION 
Obesity, defined as a body mass index (BMI) of ≥ 30 kg/m2, is one of the most pressing 
public health issues, with over one-third of adults in the U.S. obese1.  Moreover, type 2 diabetes, 
a common complication of obesity, affects approximately 26 million adults in the U.S.2; indeed, 
large epidemiologic cohort studies have found a strong independent association between obesity 
and the development of type 2 diabetes3. Insulin resistance (IR), in which glucose uptake by the 
peripheral tissues targeted by insulin is reduced, contributes to the development of type 2 
diabetes4. IR is present in obesity and is considered a mediator in the obesity-type 2 diabetes 
pathway, thus increasing the risk of developing atherosclerosis. 
Lifestyle modification, consisting of a reduction in energy intake, increase in energy 
expenditure, and behavioral strategies to support these changes, is the cornerstone of weight loss 
treatment and ultimately the prevention of type 2 diabetes 5and cardiovascular disease (CVD)6,7. 
Research has shown that even modest weight loss (5-10% of initial weight) is associated with 
improvements in a number of obesity-related comorbidities, including hypertension, 
dyslipidemia, and diabetes8. Results from the National Health and Nutrition Examination Survey 
found that about 57% of women and 40% of men pursued weight control methods9; these 
methods often produce successful weight loss for the short term10. However, long-term weight 
maintenance after intentional weight loss is difficult to achieve10, and weight regain is common, 
with up to 80% of those who lost at least 10% of their body weight failing to maintain this 
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weight for over one year11. This failure to maintain a healthy weight can lead to increased risk 
for the development of type 2 diabetes. 
A potential mechanism in the pathway between obesity and IR is inflammation. Adipose 
tissue (AT) is an active endocrine organ capable of producing a diverse group of substances, 
including pro- and anti-inflammatory cytokines12. Interleukin (IL)-6 and tumor necrosis factor-
alpha (TNF-α) are two widely researched pro-inflammatory cytokines13 that are implicated in the 
development of IR. IL-6 is elevated in obesity14, and is associated with hyperglycemia15. 
Likewise, excess adipose tissue produces an increased concentration of TNF-α3, which can 
impair insulin receptor signaling16.  
In contrast, adiponectin and IL-10 are anti-inflammatory cytokines, and decreased serum 
levels of these cytokines are associated with obesity and the development of IR. Adiponectin is 
known to have a protective effect against atherosclerosis3. Plasma levels of adiponectin 
positively correlate with insulin sensitivity (IS)17, and it is thought that adiponectin accelerates β 
oxidation of free fatty acids in skeletal muscle, thus improving the peripheral action of insulin18. 
IL-10 is known to have anti-atherogenic properties19 through the inhibition of a number of 
immune and inflammatory responses20. However, little is known about the association between 
IL-10 and insulin action21, although it has been shown to be negatively correlated with fasting 
plasma glucose22 and positively correlated with IS21,22.  
Obesity and IR are complex disorders that result not only from environmental and 
behavioral influences, but also from genetic influences15,23. Single-nucleotide polymorphisms 
(SNPs) in both pro- and anti-inflammatory cytokine genes have been well studied, but their 
association with obesity, weight regulation, and IR has not been clear24. The IL-6 -174 G>C 
polymorphism has been associated with BMI25 and fasting insulin26; however, data on the role of 
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this polymorphism in the pathogenesis of obesity and type 2 diabetes is mixed27. The effects of 
variants in TNF-α are equivocal28, but have been linked to higher glucose levels29, increased risk 
for type 2 diabetes30, less weight loss in bariatric surgery patients31, and increased waist 
circumference in women32.  
Variants in adiponectin have been associated with increased risk for obesity, although a 
recent meta-analysis revealed that the association between adiponectin SNPs and weight is 
inconsistent24. A meta-analysis on adiponectin variants and its role in IR found that some SNPs 
modulated the risk for IR while others did not33. IL-10 SNPs have been linked to BMI34,35 and 
waist circumference35. The association between IL-10 polymorphisms and insulin indices is 
understudied in the literature, and the results have been mixed36. Some studies have found an 
association with fasting glucose and HOMA-IR34,37, while others show a lack of association with 
glucose35 or the metabolic syndrome38.  
SNPs in cytokine genes have been shown to be associated with body weight, cytokine 
concentration, and IR. Therefore, it is possible that SNPs in cytokine genes may modify the 
association between weight and cytokine concentration, as well as weight and IR. Specifically, 
individuals carrying a particular allele and are obese may have higher HOMA levels compared to 
individuals of the alternative allele39, and weight loss may have a greater effect on cytokine 
concentration and HOMA for carriers of the variant allele compared to wild type allele carriers40. 
Thus it is plausible that cytokine genes can interact with weight change and other genes to affect 
IR. 
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1.1 SPECIFIC AIMS 
There is evidence that weight loss is effective at reducing inflammation and improving 
insulin action, and may be influenced by genetic makeup. However, the majority of studies have 
focused on individuals categorized as having class III obesity (BMI ≥40 kg/m2) who have lost an 
extreme amount of weight through bariatric surgery41; results from intervention studies have 
been mixed. In addition, the effect that weight regain has on inflammation and IR, as well as the 
role that cytokine  SNPs play in weight regain is underexplored in the literature. Given the role 
of obesity in the development of inflammation and type 2 diabetes, the fact that regain after 
weight loss is common, and the influence of genes on obesity and the development of type 2 
diabetes, it is important to explore the interrelationships among weight changes, cytokines, SNPs 
in cytokine genes, and IR in order to devise strategies to best reduce weight, improve 
inflammation, and reduce the risk for type 2 diabetes. Therefore, in a group of obese adults who 
lost and regained at least 10 pounds during a behavioral weight loss intervention, the aims of this 
dissertation are to: 
1. Determine the longitudinal associations between percent weight change and percent 
change in cytokines (IL-6, TNF-α, adiponectin, and IL-10) from baseline to 24 months. 
2. Determine the effects of percent weight change on percent change in insulin indices 
(fasting plasma insulin and IR [HOMA-IR]) from baseline to 24 months. 
3. Explore the association between cytokine genes, cytokine concentration, and IR during a 
weight loss intervention. 
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2.0  REVIEW OF THE LITERATURE 
 
2.1 OVERVIEW OF OBESITY 
Obesity, defined as having a body mass index (BMI) of ≥30 kg/m2, is a complex disorder 
resulting from an interaction among genetic, behavioral, and environmental factors42-45. Obesity 
rates have rapidly increased within the last few decades45, reaching epidemic proportions44,46,47. 
This increase suggests that it is environmental and behavioral changes, rather than biological 
changes, that are responsible for the increased rates44. Indeed, the current nutritional environment 
in the U.S. is characterized by excess availability and consumption of energy-dense foods 
concurrent with an increase in sedentary lifestyle42,45. The increased obesity rates have led to an 
increase in the number of complications, including cardiovascular disease48, dyslipidemia, the 
metabolic syndrome49, and certain cancers50-52. Given the combination of these factors, obesity is 
one of the most pressing public health issues globally47.  
In the U.S., results from the 2009-2010 National Health and Nutrition Examination 
Survey reveal that the age-adjusted prevalence of obesity is approximately 36%, with rates for 
men being 35.5% and for women 35.8%1. While there are subtle differences in the prevalence of 
obesity between men and women, there are significantly larger differences between racial/ethnic 
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groups1. The prevalence of class II (defined as BMI of 35-<40 kg/m2) and class III (defined as 
BMI of ≥40 kg/m2) obesity is growing, with about 15% of the population having a BMI ≥35 
kg/m2 1. These numbers give a startling picture of the magnitude of the obesity epidemic. 
2.2 APPROACHES TO OBESITY TREATMENT 
There are three approaches used to treat obesity: bariatric surgery, pharmacotherapy, and 
standard behavioral therapy (SBT) for weight loss. Studies have shown that bariatric surgery can 
result in large weight loss that is sustained over time, leading to improvements in 
cardiometabolic risk factors53. However, there are limitations to bariatric surgery, including long-
term health effects of the procedure and the fact that it is only available to the extremely obese or 
the obese with co-morbidities such as type 2 diabetes53. Pharmacotherapy such as orlistat and 
sibutramine are effective in regulating weight, but as with bariatric surgery, they have 
limitations, such as adverse health effects and contraindication to their  use54. SBT, which 
consists of a reduction in energy intake, increased energy expenditure, and behavioral therapy, is 
the standard approach to weight loss treatment6. It has been shown to be effective in the 
reduction of weight5. Despite its effectiveness, individuals tend to regain weight and can be 
susceptible to weight cycling. 
2.2.1 Difficulties with weight loss maintenance and risk for weight cycling 
Weight loss is common, with about 57% of women and 40% of men currently attempting 
to lose weight9. Participants who enroll in weight loss studies tend to lose weight quickly, often 
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in the first 6 months55, and it has been shown that initial weight loss as low as 5% is enough to 
prevent or improve cardiometabolic diseases56. However, weight maintenance after weight loss 
has been proven difficult to achieve; only 20% of individuals are successful in long-term weight 
maintenance57,58. In fact, the lack of long-term success in behavioral therapy aimed at weight loss 
has been reported in the literature for over 30 years56,59. Most who intentionally lose weight will 
regain about 35% of the weight that is lost within a year56,60 and about 95% within five years57, 
thus entering into a pattern of weight loss and regain known as weight cycling. Furthermore, 
although modest weight loss can improve health outcomes, it is still unclear whether these 
improvements remain or are attenuated with weight regain61. A meta-analysis of weight loss 
clinical trials with a minimum of 1-year follow-up revealed that the mean 6-month weight loss of 
subjects based on a review of 80 studies (N=18,199 completers) was achieved in all lifestyle 
modification groups, with the highest for those assigned to a very-low-energy diet (16%), 
followed by meal replacements (9.6%), diet plus exercise (8.5%), diet alone (5%), and exercise 
alone (2.7%).  However, weight regain in the long-term (ranging from 12-48 months) was 
detected in all three groups with the very-low-energy diet group experiencing the largest and 
most rapid weight regain62. The results of the meta-analysis reveal the complex nature of weight 
maintenance after successful weight loss56. 
2.3 OBESITY AND INSULIN RESISTANCE 
One of the most prevalent complications of obesity is the development of type 2 diabetes;  
currently about 26 million adults in the U.S. are affected by the disease63. Uncontrolled type 2 
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diabetes can lead to a host of health problems, including myocardial infarction, stroke, blindness, 
and renal failure64. A major contributor to the development of type 2 diabetes is insulin 
resistance (IR), which is defined as the reduction in glucose uptake in adipose and skeletal 
muscle tissues4. Insulin is an essential hormone that increases glucose disposal in skeletal muscle 
and adipose tissue, while inhibiting gluconeogenesis in liver, with the goal of regulating glucose 
homeostasis65. Insulin also modulates the metabolism of fats66, targets the heart and vascular 
endothelium, and helps maintain metabolic and cardiovascular homeostasis67,68. Adipose tissue 
IR contributes to the development of cardiovascular diseases such as atherosclerosis through 
such mechanisms as increasing the release of free fatty acids into the circulation69. It is also 
believed that IR may predate the development of type 2 diabetes by 10-20 years70, emphasizing 
the importance of preventing and correcting this phenomenon in order to prevent future serious 
medical complications.  
A wealth of empirical studies have examined the association between obesity and IR, 
although this association is not definite71. Epidemiological studies have found a positive 
association between IR and various measures of adiposity, including body weight, waist 
circumference, and fat mass72. In addition, major population-based studies, such as the Diabetes 
Prevention Program5,73, have shown that lifestyle modification resulting in weight loss is 
associated with changes in IR. It is still unclear what the effects of weight regain are on IR since 
few studies have examined this relationship.  
Patterns of weight loss and regain, or weight cycling, have been reported to be associated 
with insulin concentration and/or IR, but the association is not conclusive74. Some studies found 
a significant association75, while others have not76,77. The inconclusiveness is likely due to the 
challenges associated with finding the appropriate definition for weight cycling, and limitations 
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of studies that do investigate this phenomenon, such as inclusion of both unintentional and 
intentional weight loss, cross-sectional rather than longitudinal studies78, and lack of detail 
regarding amount and timing of weight regain76,78. Clearly, this is an important phenomenon in 
terms of weight maintenance and overall health, and needs to be explored further in the 
literature.   
2.3.1 Adipose Tissue Pathology and Insulin Resistance 
In response to obesity, white adipose tissue rapidly expands through adipocyte 
hypertrophy and hyperplasia in order to maintain whole-body energy homeostasis79. This 
expansion can lead to two mechanisms in the development of metabolic dysfunction: 1) the 
release of free fatty acids into the circulation, eventually leading to ectopic fat deposition80; and 
2) a reduction in blood flow that causes an inflammatory state, possibly due to hypoxia and 
adipocyte necrosis81. 
2.3.1.1 Adipose Tissue Expansion and the Overflow Hypothesis 
Adipose tissue normally functions as a buffer by suppressing the release of free fatty 
acids into circulation and increasing triglyceride clearance47. However, in obesity, adipose tissue 
becomes overloaded with triglycerides, decreasing the buffer capacity for fat storage in 
adipocytes82. Thus, the “overflow hypothesis” states that there is limited capacity for adipose 
tissue to store fuel; therefore, long-term energy intake can result in the overflow of excess lipids 
to non-adipose tissue in places such as the liver and muscle, disrupting their functions83 and 
causing IR47. It has been shown that adipocyte hypertrophy is an independent risk marker of 
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IR84. Free fatty acids can also activate the inflammatory response by increasing local 
extracellular lipid concentrations, leading to macrophage accumulation79,85.  
2.3.1.2 Inflammatory Processes in Adipose Tissue Expansion 
Obesity is characterized by chronic low-grade inflammation, and this inflammatory state 
has a critical role in the pathogenesis of metabolic dysfunction81. The pathological expansion of 
white adipose tissue is characterized by the rapid growth of fat pad, leading to hypoxia86, 
macrophage infiltration, up-regulation of pro-inflammatory markers, and down-regulation of 
anti-inflammatory markers79,81. Therefore, the endocrine function of white adipose tissue 
depends on secretory processes of both adipocytes and the stromal vascular cells87, particularly 
macrophages, and obesity can modify the secretory status of white adipose tissue81. There are 
two types of macrophages that are part of white adipose tissue: classically activated (M1) and 
alternatively activated (M2) macrophages. M2 macrophages are considered the anti-
inflammatory phenotype and predominate in white adipose tissue of lean individuals, while M1 
macrophages are pro-inflammatory in nature and predominate in white adipose tissue of obese 
individuals88. Although the mechanisms are not completely understood, obesity leads to immune 
imbalance in white adipose tissue, with a shift from M2 anti-inflammatory macrophages to the 
M1 type89. It has been shown that weight loss and maintenance result in a reduction of 
macrophages and a decrease in the pro-inflammatory profile in obese individuals90. 
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2.3.2 Weight Loss Interventions Investigating the Impact of Weight Change on Insulin 
Resistance  
The effects of weight loss from SBT on IR are outlined in 13 studies53,61,72,91-100 (Table 2-
1). The interventions ranged in duration from four weeks to two years. Only four studies53,91,93,97 
had interventions lasting a year or longer, highlighting the lack of long-term weight loss 
interventions reported in the literature. Six53,61,72,91,94,99  of the thirteen studies had more than one 
follow-up time point. Of these six studies, only one53 reported no regain in either group. The 
amount of weight regained from period of weight loss to the end of the study ranged from 1.5% 
to 31.4%. Overall, the majority of studies found that weight loss decreased HOMA-IR 
(homeostatic model assessment-insulin resistance), regardless of the amount of weight lost. Four 
studies61,72,91,99 revealed that when weight was regained at follow-up, there was some attenuation 
of improvement in HOMA-IR that were observed after weight loss. However, HOMA-IR was 
still lower at follow-up compared to baseline, suggesting that a certain amount of weight loss 
may have some long-term protective effects for IR.  
These studies reveal that SBT for weight loss has a positive effect on reducing IR. 
Despite the short-term nature of most of the interventions and variations in sample size, 
populations studied, and intervention components, it is clear that weight change has a positive 
effect on IR. However, more attention needs to be given to the role of weight regain in these 
factors. 
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2.4 CYTOKINES, OBESITY, AND INSULIN RESISTANCE 
The link between obesity and a chronic low-grade inflammatory state has been 
established from epidemiological studies dating back to the 1950s, although the mechanisms 
behind this association have not been fully elucidated89. One potential mechanism is the 
dysregulation in the balance between pro- and anti-inflammatory cytokines, leading to chronic 
low-grade systemic inflammation that contributes to the development of cardiometabolic 
disorders88. Cytokines are involved in a variety of biological processes, including lipid and 
carbohydrate metabolism, angiogenesis, immune response, adipocyte proliferation and 
differentiation, and blood pressure regulation88. The literature has shown cytokine concentrations 
to be altered in obesity, and weight loss generally results in improvement in cytokine levels90. 
However, very few studies have examined the effect of weight regain and weight cycling on 
obesity-associated inflammation; therefore, a significant gap in the scientific literature remains74.  
The paragraphs that follow provide an overview of four cytokines that are the focus of the 
proposed dissertation study: IL-6, TNF-α, adiponectin, and IL-10 (Table 2-2).  
2.4.1 IL-6 
IL-6 is a pleiotropic cytokine that has both pro- and anti-inflammatory properties15, 
depending partly on the tissues that are involved101. For example, in skeletal muscle, IL-6 
increases glucose metabolism102, whereas opposite effects are observed involving adipose 
tissue103. IL-6 has a variety of functions, including inducing hepatic C-reactive protein 
production, a marker of cardiovascular disease104; increasing TNF-α secretion; and regulating 
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hematopoiesis and host defense mechanisms105. IL-6 has been implicated in the development of 
atherosclerosis, as IL-6 mRNA is present in atherosclerotic arteries at a rate that is 10-40 times 
higher than in non-atherosclerotic arteries106. It is produced by several cell types, including 
endothelial, skeletal and smooth muscle, adipocytes, monocytes, and fibroblasts107. About 15% 
to 35% of the total concentration of IL-6 originates from adipose tissue108, of which the majority 
comes not from mature adipocytes but from cells representing the stromal vascular fraction107.  
Population-based studies have shown that IL-6 is elevated in individuals who are obese, 
and IL-6 plays a key role in the interaction between obesity, inflammation, and cardiovascular 
disease109-111. For example, among adult women, those who were obese had a significantly 
higher concentration of IL-6 compared with women who were lean112. Another study of 
overweight and normal weight boys found IL-6 levels to be significantly higher in overweight 
compared with normal-weight boys113.  The role that weight loss plays in reducing IL-6 levels is 
controversial and may be dependent on the amount and mechanism of weight loss. For example, 
it has been shown that IL-6 concentrations improved with an 8% weight loss in individuals on a 
low-calorie, low-to-moderate fat intake diet114, but that a 3% weight loss was not enough to 
provide significant improvements in IL-6 concentration among overweight individuals on a high-
fat, low-calorie diet115. The disparate outcomes may be due to differences in the duration of the 
weight loss intervention as well as the intervention itself. In addition, it has been shown that 
exercise-induced weight loss did not have a significant impact on IL-6 concentration but that 
diet-induced weight loss did116. Only one study investigated the association between weight 
regain and IL-6 among individuals who intentionally lost weight as part of a 6-month behavioral 
intervention61, and investigators did not find a significant change in IL-6 when weight was 
regained at 12 months.  
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The association between IL-6 and obesity has been consistently shown in the literature; 
however, the association between IL-6 and IR is controversial107. There is some debate on 
whether IL-6 improves insulin sensitivity, due to its release into circulation post-exercise and the 
fact that this period is the time when insulin action is enhanced, or whether IL-6 promotes IR117. 
Nevertheless, studies have shown IL-6 to contribute to the development of IR by promoting 
lipolysis in adipocytes, increasing hepatic fatty acid synthesis, and increasing plasma triglyceride 
concentration via inhibiting lipoprotein lipase activity in AT118. It also has been shown that IL-6 
decreases the action of insulin15; one study found a significant positive correlation between 
plasma insulin concentration and IL-6 in both diabetic and non-diabetic obese women and 
healthy lean women119. In a study of 142 men and women with varying levels of obesity, insulin 
sensitivity, and glucose tolerance, there was a dose-response associated with plasma 
concentrations of IL-6, with those having type 2 diabetes with the highest concentration of IL-6, 
followed by those with impaired glucose tolerance, and those with normal glucose tolerance 
having the lowest concentration of IL-622. A large population-based study also found IL-6 to be 
an independent risk factor for the development of type 2 diabetes120. 
2.4.2 TNF-α 
TNF-α is a pro-inflammatory cytokine that is primarily derived from monocytes and 
macrophages86,107. It has a wide range of pro-inflammatory properties13,121, and its primary role is 
in stimulating the acute phase of inflammation122. TNF-α has been shown to be overexpressed in 
obesity; it has been found to be produced up to 7.5 times more in the adipose tissue of obese 
compared to non-obese individuals123. Therefore, it is considered an important mediator in the 
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association between obesity and IR16. Epidemiological studies have found TNF-α to be 
positively associated with BMI124. Obese individuals have been shown to have higher 
concentrations of TNF-α compared to non-obese individuals125. However, there does not appear 
to be a difference in expression and production between subcutaneous and visceral fat126. It has 
been shown that weight loss improves inflammation127, but the role of weight loss on improving 
TNF-α concentration is inconsistent. Some studies have shown weight loss to reduce 
concentrations of TNF-α128,129, while other studies have not61,130,131.  It is important to note that 
one of the studies129 that found a significant decrease in TNF-α after weight loss had on average, 
a 15%  reduction in weight, whereas the other studies61,130,131 had an average weight reduction  
between 3% and 7%. This suggests that amount of weight loss may determine cytokine 
concentration, but this is not definite. There are limitations to these studies, in particular, the 
short duration which inhibited the ability to investigate the effect of patterns of weight loss and 
regain on TNF-α. Only one study investigated the association between weight regain and TNF-α 
among individuals who intentionally lost weight as part of a behavioral intervention61, and 
investigators did not find TNF-α concentrations to significantly change during the weight regain 
period. 
TNF-α has been known to interfere with insulin action, and although the mechanisms 
behind this are not completely clear, it is thought that it inhibits tyrosine kinase activity of the 
insulin receptor103,132, which is crucial in the binding of insulin to its receptor16. Obese mouse 
models lacking TNF-α function have shown improved insulin sensitivity133. Since TNF-α has a 
role in insulin action, it is plausible that TNF-α is also associated with the development of IR. 
Epidemiological studies have investigated this association, but have produced inconsistent 
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results69,124. TNF-α has also been known to affect lipid metabolism121 and is positively correlated 
with triglyceride levels, increasing the risk of coronary heart disease134. 
2.4.3 Adiponectin 
Adiponectin, also known as ACRP30, AdipoQ, GBP28, and apM1, is a cytokine highly 
expressed in adipose tissue107. Adiponectin has multiple functions, including regulating insulin 
sensitivity, energy homeostasis, and tissue remodeling111. Adiponectin is a particularly 
interesting cytokine in that, unlike others, it is reduced in obesity, and reduced levels are 
associated with the development of IR, type 2 diabetes, and coronary artery disease13. There is 
also a strong correlation between high concentrations of adiponectin and insulin sensitivity107. 
Other cardioprotective properties of adiponectin include the modulation of TNF-α inflammatory 
response, where it reduces secretion of TNF-α from macrophages135, and the up-regulation of IL-
10, leading to anti-inflammatory activity136. Adiponectin also inhibits monocyte adhesion to 
endothelial cells, preventing atherosclerotic plaque formation111. 
Epidemiological studies have shown adiponectin to be associated with BMI and the 
development of IR in various populations. In a large study of lean Japanese men and women 
without severe illness, adiponectin was negatively correlated with BMI, fasting plasma glucose, 
insulin levels, and IR137. Weight loss has been shown to increase adiponectin levels in some 
studies138 but not others139,140. These differences are likely due to differences in study 
participants (e.g. both male and female participants vs. female only) and duration of the weight 
loss intervention. Also, there may be conflicting results regarding the amount of weight loss that 
is adequate to produce desired changes in adiponectin. For example, a study among participants 
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who lost 10% or more of their initial body weight showed improvements in adiponectin138, while 
other studies among participants who lost <10% of their initial body weight showed no 
improvements in adiponectin141,142. Only three studies have investigated the association between 
weight regain and adiponectin among individuals who intentionally lost weight as part of an 
intervention61,143,144. Two studies showed increases in adiponectin despite weight regain61,144, 
while the other one reported no significant association between weight regain and adiponectin143.  
It is possible that the differences between these three studies have to do with study design. The 
studies that found increases in adiponectin with weight regain included multiple time points, 
whereas the study that did not report a significant association examined weight regain in the 
context of a single event that occurred during a specific time period (a “weight regain period”). 
2.4.4 IL-10 
IL-10 is an anti-inflammatory cytokine that is primarily produced by M2 macrophages 
and Th2 lymphocytes145. Its anti-inflammatory nature is due in part by inhibiting the production 
of several pro-inflammatory cytokines such as IL-6 and TNF-α89. Another atherogenic property 
of IL-10 includes the prevention of atherosclerotic lesion development146  and stability147. In the 
area of obesity, lifestyle modification, and weight loss research, IL-10 is an extremely 
understudied cytokine. A great majority of the studies on IL-10 have been conducted in non-
humans; if they involved humans, they were bariatric surgery studies, or involved participants 
with acute and/or allergic inflammatory conditions. Therefore its expression in obesity is rather 
conflicting where it has been shown to be either increased148 or decreased149.  
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Very few studies have reported examining the effect of weight loss on IL-10 
concentration. One weight loss study in which  Korean participants lost an average of 7% of their 
initial body weight over 12 weeks, circulating IL-10 levels significantly increased150. However, 
another study of U.S. gastric bypass surgery patients found that even with a 22% decrease in 
weight at 12 weeks post-surgery, there were no significant changes in IL-10 concentration151. 
The disparate outcomes may be due to patient characteristics (e.g. differences in racial groups), 
or to sample size, as the former study had 78 participants whereas the latter study only had 15. It 
may also reveal the potential differences in outcomes based on method of weight loss. Only one 
study investigated the association between weight regain and IL-10 among individuals who 
participated in a weight loss intervention61. A significant change in IL-10 with weight regain was 
not observed.  
The literature on the association between IL-10 and IR is just as obscure. It is likely that 
IL-10 is associated with IR via the suppression of pro-inflammatory cytokines that interfere with 
insulin signaling such as TNF-α152. However, there is variability in the literature in the 
association between IL-10 and IR. For example, IL-10 was not shown to be associated with 
HOMA-IR in African-American, overweight/obese participants153. In contrast, a study conducted 
in Caucasian,  slightly overweight (average BMI=26 kg/m2) participants found IL-10 to be 
positively associated with insulin sensitivity even after controlling for BMI21.  
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2.5 WEIGHT LOSS INTERVENTIONS INVESTIGATING THE IMPACT OF 
WEIGHT CHANGE ON CYTOKINES AMONG OVERWEIGHT/OBESE ADULTS 
The effects of SBT for weight loss on cytokines are outlined in 16 studies61,92,129-131,138-
141,149,154-159 (Table 3). The interventions ranged in duration from 4 weeks to 2 years, although the 
great majority of the interventions were 6 months or shorter. Overall, there were some mixed 
results regarding improvement in cytokines after intervention. For example, out of the 12 studies 
that investigated adiponectin, five found a significant increase in concentration post-
intervention138,139,155-157 while seven did not61,130,131,141,149,154,159. Ten studies investigated the 
effects of a weight loss intervention on IL-6 concentration. Of these, intervention results showed 
a significant decrease in IL-6 in six studies92,129,130,139,140,158. Seven studies investigated the 
effects of weight loss intervention on TNF-α61,129-131,156,157,159. Overall, none of the studies 
showed a major impact of weight change on TNF-α. However, one study130 did find a significant 
decrease in TNF-α post-intervention in those who had impaired glucose tolerance, but not in 
those with normal glucose tolerance or type 2 diabetes. This suggests that weight loss 
interventions may be beneficial in reducing TNF-α in those with pre-diabetes, but may not be 
beneficial in reducing TNF-α concentration in healthy individuals or in individuals with overt 
diabetes. Lastly, only three studies investigated the effects of a weight loss intervention on IL-
1061,149,156.  In all three studies, there were no significant changes in IL-10 that corresponded with 
changes in weight.  
The lack of significant results for some of the cytokines as well as inconsistency in 
results between the studies points to a number of limitations of these studies. First, the majority 
of these studies only collect data at one time point; therefore, the fluctuations in weight and 
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cytokine concentrations are not captured. Second, the majority of these studies have total sample 
sizes smaller than 50, with two or more comparison groups of approximately 10 or so 
individuals. These small samples may lead to inaccurate results. Finally, the majority of these 
studies had brief (e.g. 4 weeks) short-term interventions, which may not have been long enough 
to produce the desired results. Additional limitations included variability in the intervention 
components and differences in the observed weight loss, which may have contributed to 
inconsistent outcomes. It is interesting to note that the intervention studies that had the most 
weight loss produced the most improvement in some of the cytokines. For example, in one study 
where the mean percent weight loss post-intervention was 15% and 3% in the treatment and 
control groups, respectively, the treatment group had greater improvements in adiponectin and 
IL-6 compared to the control group139.  
2.6 CYTOKINE GENE POLYMORPHISMS AND INSULIN RESISTANCE 
Cytokines play a role in the pathogenesis of IR, and single-nucleotide polymorphisms 
(SNPs) in cytokine genes may be related to the predisposition to and/or different clinical features 
or outcomes of IR160. Thus, SNPs in cytokine genes could partly explain the variability in 
cytokine production, and the greater predisposition to certain health outcomes which are 
mediated by changes in cytokine production161. Table 4 outlines eight SNPs in the genes 
encoding IL-6, TNF-α, adiponectin, and IL-10, which are also discussed in depth below.  
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2.6.1 IL-6 
The IL-6 gene is located on chromosome 7p21162, and has been linked to the development 
of type 2 diabetes163. The rs1800795 SNP is a G-to-C substitution at position -174 in the 
promoter region of the IL-6 gene, and is the most commonly studied IL-6 SNP164. There is 
evidence that this SNP represents a functional change involved in transcription of the IL-6 gene, 
thus making it a risk factor for a number of diseases165,166. Indeed, many studies have revealed 
this SNP to be associated with health outcomes such as rheumatoid arthritis167 and coronary heart 
disease168. Studies have also shown the C variant allele of rs1800795 to be associated with higher 
IL-6 levels26,169 and BMI169, particularly although this association is controversial.  
The association between rs1800795 and IR is also controversial, with the literature 
revealing mixed results. For example, a study among Swedish Caucasian males without obesity 
and diabetes found that those who had the GG genotype had lower HOMA-IR compared to C 
allele carriers170. In contrast, a study in Turkish participants with and without polycystic ovary 
syndrome (PCOS) found no association between rs1800795 genotypes and HOMA-IR in both 
those with PCOS and healthy controls171. These results are echoed by a study including Italian, 
obese, non-diabetic men and women172, and by a study that included lean and obese, non-
diabetic Indian women173.  
Only a few studies have examined the interaction between weight indices, cytokine 
concentration, and cytokine variants in relation to IR39,174,175. A study among Italian men and 
women with and without diabetes found C allele carriers to have a significant association 
between IL-6 and IR in those with type 2 diabetes. This same association was not observed 
among participants with the GG genotype who were also diabetic, or among those without 
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diabetes, regardless of their genotype174. Two other studies found BMI to significantly modify 
the association between rs1800795 and IR, with higher BMI being associated with higher 
HOMA-IR in those who were of the CC genotype compared to G allele carriers39,175. No studies 
have investigated the interaction between rs1800795 and changes in weight on changes in IR.  
2.6.2 TNF-α 
The TNF-α gene is located on chromosome 6p21176,177 in the class III region of the major 
histocompatibility complex177. Two SNPs, a G-to-A substitution at position -308 (rs1800629), 
and a C-to-A substitution at position -863 (rs1800630), have been  researched and associated 
with a number of health outcomes, including advanced-stage endometriosis177 and rheumatoid 
arthritis178. The rs1800629 SNP is the most commonly researched TNF-α gene SNP and the A 
allele has been associated with increased body fat content179. It has also been suggested that 
rs1800629 influences circulating TNF-α levels32, although this association has not been observed 
in all studies180. In the context of obesity, rs1800630 is understudied. Only two studies have 
investigated the association of this SNP with obesity, and one found a significant association176, 
while the other did not28. An association between rs1800630 and circulating TNF-α levels has 
also been found181. 
Evidence suggests that SNPs in the TNF-α gene can modify an individual’s risk for 
obesity-associated complications such as IR164. Indeed, these SNPs have been investigated 
within the context of type 2 diabetes and features of the metabolic syndrome, with mixed 
results176. The results of two European studies of healthy overweight/obese adults did not show 
an association between IR and rs1800629180,182. A study among Mexican women with gestational 
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diabetes found that participants with the GG genotype had higher HOMA-IR compared to those 
carrying an A allele183. Only one study investigated the association between rs1800630 and IR, 
with non-significant findings176. This highlights the need for more research on this particular 
variant. 
There are a lack of studies on the interaction between TNF-α gene SNPs and weight 
change and its effect on IR. It is important to investigate these relationships in order to determine 
the best possible intervention to reduce the risk of IR in those most susceptible.  
2.6.3 Adiponectin 
The gene that encodes adiponectin (ADIPOQ) is located on chromosome 3q27 and 
consists of three exons and two introns184. The gene is located in a region where a susceptibility 
locus for type 2 diabetes and cardiovascular disease has been mapped184,185. There are several 
ADIPOQ SNPs that have been identified, with the most common being the rs1501299 (+276 
G>T), which is a G-to-T substitution in intron 2 and rs266729 (-11377 C>G), a C-to-G 
substitution in the immediate 5’ flanking region186. ADIPOQ has been associated with circulating 
levels of adiponectin, as well as with obesity187  and obesity-associated co-morbidities164.  
For rs1501299, several studies have found a significant difference between genotypes in 
circulating adiponectin levels, with individuals of the GG genotype having lower baseline 
adiponectin compared to T allele carriers184,188,189. In contrast, several studies found no such 
association190-197.  For rs266729, some studies have found a significant difference between 
genotypes in adiponectin levels, with individuals of the GG genotype having lower levels 
compared to C allele carriers193,198; other studies have not found such an association191,192,199. 
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As with circulating adiponectin levels, the association between ADIPOQ SNPs and IR 
has been equivocal. For rs1501299, studies have revealed a significant association between 
genotype and HOMA-IR184,190; however, one study showed that individuals with the GG 
genotype had higher baseline HOMA-IR compared to T allele carriers184, while the other study 
showed that the TT genotype had higher HOMA-IR compared to G allele carriers190. Reasons for 
the differences could be due to minor allele frequency (MAF) distribution in populations; 
however, the rs1501299 MAF is similar across all racial/ethnic groups. It is likely that 
differences in populations and sample sizes are responsible for the disparate results. Fewer 
studies have examined the role of rs266729 in IR, of which the majority of studies did not find 
an association between genotype and HOMA-IR. Only one study found a significant difference 
among genotypes in relation to HOMA-IR200. This study was conducted among 
overweight/obese non-diabetic children (mean age ~11 years) and found participants with the CC 
genotype to have lower HOMA-IR compared to G allele carriers.  
A trend toward an interaction between the rs1501299 SNP and percent body fat in 
affecting IR has been observed. Also, a significant association between rs1501299 and IR was 
observed only in those with a higher percent body fat, with G allele carriers with ≥41% body fat 
having higher HOMA-IR than TT genotype190.  
2.6.4 IL-10 
The IL-10 gene is composed of five exons, and is located in chromosome 1q31-3237.  The 
three most commonly researched SNPs in the promoter region of the gene are the G-to-A 
substitution at position -1082 (rs1800896), a C-to-T substitution at position -819 (rs1800871), 
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and a C-to-A substitution at position -592 (rs1800872)201. These SNPs have been associated with 
a number of diseases, including Crohn’s disease201, cardiovascular disease36, and type 2 
diabetes37.  Some studies have found a significant association between IL-10 SNPs and both 
obesity and circulating IL-10 levels; however, there is variability in results. For example, a study 
among overweight/obese Caucasian Italian adults with and without type 2 diabetes found a 
significant association between genotype for rs1800872 and both BMI and circulating IL-10 
levels; individuals with the AA genotype had a higher BMI and lower IL-10 levels compared to 
C allele carriers34. Within the same study, there were no significant differences between 
genotypes for the rs1800896 SNP and BMI or IL-10 levels. Another study conducted among 
obese Caucasian Spanish adults found no significant association between genotype for 
rs1800871 and BMI. However, after morbidly obese participants were removed from the 
analysis, the association was significant; compared with individuals with the CC genotype, those 
carrying the T allele had a higher BMI. There was no association between genotype and IL-10 
levels in either analyses35. 
Although IL-10 has been shown to be associated with obesity, there is a lack of literature 
investigating the interrelationships between IL-10 polymorphisms, obesity, and IR. Only two 
studies have examined the association between IL-10 polymorphisms and IR. A study among 
women with PCOS and healthy controls did not find a difference among the rs1800896 and 
rs1800871 genotypes for HOMA-IR202. The study conducted among overweight/obese 
Caucasian Italian adults with and without type 2 diabetes also did not find a difference among 
the rs1800896 genotypes and HOMA-IR, but did find that individuals with the AA genotype for 
rs1800872 had higher HOMA-IR compared with C allele carriers34. 
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2.7 WEIGHT LOSS INTERVENTIONS, CYTOKINE POLYMORPHISMS, AND 
INSULIN RESISTANCE 
How genotype affects IR in response to a dietary, physical activity, and/or behavioral-
based weight loss intervention is largely underexplored in the literature.  A study among non-
diabetic overweight/obese Korean adults enrolled in a 12-week low-calorie dietary intervention 
found that, for the ADIPOQ SNP rs266729, regardless of genotype, individuals were able to 
significantly reduce HOMA-IR post-intervention. On the other hand, for the adiponectin 
rs1501299 SNP, individuals with the GG genotype significantly decreased HOMA-IR after the 
intervention, but T allele carriers did not have a significant decrease in HOMA-IR after weight 
loss191. In a separate study that included Korean adults with impaired fasting glucose or type 2 
diabetes who were enrolled in a 12-week low-calorie dietary intervention, HOMA-IR was also 
significantly reduced post-intervention in participants who had the GG genotype for the 
rs1501299 SNP; however, this was attenuated when controlling for baseline HOMA-IR levels192. 
Genotypic differences in metabolic outcomes, such as fasting glucose and insulin, 
resulting from lifestyle modification has been shown. A study among Brazilian adults with pre-
diabetes or impaired glucose tolerance investigated the association between genotype and fasting 
insulin and glucose, after a 9-month lifestyle intervention. For the TNF-α SNP rs1800629, 
individuals with the GG genotype had a significant decrease in insulin post-intervention, whereas 
those carrying the variant A allele were not able to significantly reduce insulin levels post-
intervention. The opposite was true for glucose. For the IL-6 SNP rs1800795, both individuals 
with the GG genotype and carriers of the variant C allele were able to significantly reduce insulin 
post-intervention. Only individuals with the GG genotype were able to reduce glucose 
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concentration post-intervention40. Although this study did not measure IR, the impact of lifestyle 
modification on the relationship between genotype and other metabolic variables closely related 
to IR can give clues about how an individual can respond to a lifestyle intervention according to 
his or her genotype.  
 
2.8 SUMMARY 
Obesity rates have reached epidemic proportions over the past few decades, leading to 
co-morbid conditions such as cardiovascular disease and type 2 diabetes. SBT continues to be 
among the most effective means of obesity treatment for a wide range of individuals. However, 
weight maintenance after intentional weight loss is difficult to achieve, and weight regain is 
common. An individual can then enter a pattern of weight cycling, which can lead to a decline in 
overall health. Therefore, it is important that more strategies be developed to prevent weight 
regain and thus improve or maintain health. 
IR plays a large role in the development of type 2 diabetes. One of the mechanisms that 
contribute to IR is dysfunctional adipose tissue, which is a characteristic of obesity. Another 
mechanism that links obesity to IR is chronic inflammation, where obese states are characterized 
by an increase in pro-inflammatory cytokines and a decrease in anti-inflammatory cytokines. 
SBT leading to moderate weight loss can improve both IR and inflammation, although results 
have not been consistent. Moreover, studies investigating these associations have included 
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interventions that were short in duration, or collected data at only one time point, limiting the 
ability to examine the influence of weight regain on these outcomes.  
Cytokine gene polymorphisms have been associated with IR, although the results have 
been inconsistent. Nevertheless, cytokine gene polymorphisms can be informative in determining 
risk for IR and how an individual responds to a weight loss intervention. Although a few studies 
have investigated how weight modifies the association between gene polymorphisms and IR, 
much research is still needed to reduce the ambiguity of this relationship.  
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Table 2-1. Weight loss studies examining the role of diet and exercise on insulin resistance among overweight/obese participants 
Author 
(Year) Population Treatment Treatment Length Weight Change Findings 
Naslund et al. 
(2000)91  
Obese men 
(BMI=37.1 kg/m2, 
age=42.7 y), non-
diabetic 
N=44 
Group sessions (once/wk 
for 1 h) 
1600 kcal/d 
Moderate exercise 
encouraged 
2 y; FU at 1 and 2 y baseline-1 y: -5.5%  
baseline-2 y: -4.1% 
amount of weight regain 
1-2 y: 1.5% 
HOMA: Ps had a 14.9% ↓ 
baseline-1 y (p<.05) and a 
18.9% ↓ baseline-2 y 
(p<.05); those who gained 
weight at 2 y had a smaller ↓ 
in HOMA compared to those 
who lost at 2 y (-21.6% vs. 
-15.1%,  ns) 
Krebs et al. 
(2002)72 
Obese women 
(BMI=1.7 kg/m2, 
age=43.7 y), non-
diabetic  
N=57 
8-wk milk-based diet 
(800-900 kcal); food 
gradually resumed wks 9-
12 
Groups sessions including 
info and advice on healthy 
lifestyle and weight 
control 
12-wk weight loss 
program + FU at wks 24 
and 52 
*at 1 yr,
-11.6% baseline-12 wks; 
-10.6% baseline-24 wks 
-5.9% baseline-52 wks  
regain: 
12-52 wks: 6.3% 
After 12 wks, significant 
improvement in HOMA  
(-18.1%, p<.0001); no 
improvements in insulin 
sensitivity from baseline-52 
wks 
Villareal et al. 
(2006)92 
Obese adults 
(baseline BMI=39 
kg/m2, age ~71 y),  
non-diabetic  
N=27 
Treatment: Diet and 
exercise therapy (n=17) 
• energy deficit of 750
kcal/d 
• 90-min exercise
session 3 d/wk 
• group behavioral
therapy 
Control: no treatment 
(n=10) 
26 wks Treatment group: -8.4%, 
baseline-26 wks 
Control group:  -0.7% 
baseline-26 wks 
Compared to control group, 
treatment group had a 
greater decrease in HOMA 
post-treatment (-32% vs. 
25%, p<.05) 
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Table 2-1 continued 
Author 
(Year) Population Treatment Treatment Length Weight Change Findings 
Vogeser et al. 
(2007)93 
Obese adults 
(BMI=35.7 kg/m2, 
mean age=45 y), 
Caucasian, non-
diabetic 
N=33 
Standard diet (fat limit: 60 
g; fruits/vegetables 5 
times/d; 3 meals/d) and 
structured physical 
exercise on most 
days 
1 y Median weight loss: 
-9.0 kg 
HOMA ↓ by 45% baseline-1 
y (p<.05) 
Dale et al. 
(2009)94 
Obese (BMI≥30 
kg/m2) Caucasian 
adults with insulin 
resistance 
N=72 
Treatment: diet and 
exercise advice 
Control: continued normal 
diet and exercise routine 
4 months; FU at 24 
months 
Treatment: -5.5% 
baseline-4 mos and  
-1.1% baseline-24 mos 
Control: -0.4% baseline-
4 mos and -0.8% 
baseline-24 mos 
Treatment: 4.6% regain 
4-24 mos 
Control: no weight regain 
4-24 mos  
IS: at 4 mos, treatment group 
had a greater ↑ in IS 
compared to control group 
(11% vs. 8%); at 24 mos, 
treatment group lower 
change in IS compared to 
control group (0% vs. 2%, 
ns) 
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Author 
(Year) Population Treatment Treatment Length Weight Change Findings 
Lien et al. 
(2009)61 
Obese adults 
(BMI=32.6 kg/m2, 
18+ y), non-
diabetic 
N=27 
Behavioral intervention 
• Reduced energy
intake 
• Increased exercise
• 20 weekly group
sessions 
Those who lost ≥4 kg at 
initial weight loss 
randomized to: 
Group 1: personal phone 
counseling 
Group 2: interactive Web 
site 
Group 3: Control group  
6-mo weight loss period, 
followed by 6-mo weight 
maintenance 
At 6 mos: -6.3% 
At 12 mos: -2.8% 
Weight regain from 6-12 
mos: 2.5% 
HOMA ↓ by 19.2% 
baseline-6 mos (p=.01), and 
by 18.2% baseline-12 mos 
(p=.0003) 
% ↑ in HOMA 6-12 
mos=1.3% 
Goodpaster et 
al. (2010)53 
Severely obese 
adults (BMI 35 
kg/m2 or greater,  
ages 30-55 y); no 
major/uncontrolled 
illnesses 
N=130 
Lifestyle intervention 
Group 1: diet + initial 
exercise  
Group 2: diet + delayed 
(by 6 mos) exercise  
Both groups: behavioral 
lifestyle intervention 
1 yr intervention (6- and 
12-mo FU) 
Baseline-6 mos (p=.02): 
Group 1: -9% 
Group 2: -7% 
Baseline-12 mos (ns): 
Group 1: -10% 
Group 2: -8% 
No regain at 12 mos 
No significant group 
differences in HOMA 
Table 2-1 continued 
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Author 
(Year) 
 
Population 
 
Treatment 
 
Treatment Length 
 
Weight Change 
 
Findings 
Drapeau et al. 
(2011)95 
Overweight/obese, 
postmenopausal 
women (BMI ~32 
kg/m2, age ~58 
yrs), non-diabetic 
N=46 
Calorie restriction (CR) 
group: 500-800 kcal/d 
reduction (~1100-1800 
kcal/d) 
 
CR + resistant training 
(CR+RT) group: calorie 
restriction + resistance 
training (3 d/wk) 
6 mos Mean weight loss at 6 
mos: 
CR: 7.7% 
CR+RT: 8.2% 
 
 
HOMA decreased at 6 mos 
in both groups; however, 
there was a greater decrease 
in the CR+RT group 
compared to the CR group  
(-12.2% vs. -4.2%; ns) 
Mason et al. 
(2011)96 
Overweight or 
obese (BMI≥25.0, 
≥23.0 if Asian 
American), 
postmenopausal 
women (50-75 yrs), 
non-diabetic 
N=438 
 
Group 1: Dietary weight 
loss 
Group 2: Moderate-
vigorous exercise 
Group 3: Diet + exercise 
Group 4: Control 
 
Diet: 1200–2000 kcal/d, 
30% kcal fat, 10% 
weight loss by 6 mos  
 
Exercise: 45 minutes, 
target heart rate of 70%–
85% 5 d/wk, by 7th wk 
 
Group sessions, meetings 
with dietitian  
6-mo weight loss period, 
followed by 6-mo weight 
maintenance 
At 12 mos  
Group 1: -8.5% 
(p<.0001) 
Group 2: -2.4% (p=.03) 
Group 3: -10.8% 
(p<.0001) 
Group 4: -0.8% 
HOMA at 12 mos by group: 
Group 1: -24% (p<.0001) 
Group 2: -9% (p=.19) 
Group 3: -26% (p<.0001) 
Group 4: -2% (ref) 
 
Participants who lost the 
most weight had the largest 
decrease in HOMA at 12 
mos: 
<5% weight loss: HOMA ↓ 
by 0.2 
≥5-10% weight loss: HOMA 
↓ by 0.7 
≥10% weight loss: HOMA ↓ 
by 1.1 
(p<.0001) 
Ockene et al. 
(2012)97 
Latino/Hispanic 
adults (BMI ~34 
kg/m2, age=52 y), 
non-diabetic 
N=312 
Intervention: 
• individual and group 
sessions (~60 min) 
• dietary improvement 
• increase walking by 
4000 steps/d 
1 y Intervention: lost median 
2.5 lb at 1 y 
 
Usual care: gained 
median 0.6 lb at 1 y 
 
HOMA significantly 
improved in the intervention 
vs. usual care group 
(median: -0.36 vs. -0.06, 
p=.03) 
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Author 
(Year) 
 
Population 
 
Treatment 
 
Treatment Length 
 
Weight Change 
 
Findings 
Oberhauser et 
al. (2012)98  
Obese adults (mean 
baseline BMI=41.5 
kg/m2,  age=42.3 
y), non-diabetic, 
Caucasian 
N=10 
VLCD diet (~800 kcal/d, 
4-5 meals/d), nutritional 
education, behavioral 
advice, 45 min 
exercise/wk 
3 months 16.5% ↓ in weight post-
intervention 
HOMA significantly 
decreased from baseline to 
end of study (~4.5 to ~2.0, 
p<.01) 
Beavers et al. 
(2012)99 
Overweight/obese 
postmenopausal 
women (BMI 25-40 
kg/m2,  50-70 y) 
N=80 
Calorie deficit of ~400 
kcal/day 
One counseling session at 
end of intervention period 
Weight loss intervention 
(baseline-5 mos); post-
intervention FU for 12 
mos (total=17 mos) 
Weight loss during 5-mo 
intervention: 11.4 kg; 
31.4% regain at 17 mos 
HOMA ↓ by 38.7%  
baseline-5 mos, by 18.3% 
baseline-11 mos, and by 
10.6% baseline-17 mos 
(p<.05) 
 
Changes in weight sig. 
associated with changes in 
HOMA [b(se)=2.1(0.4), 
p<.01] 
 
Weight regainers had an ↑ in 
HOMA baseline-12 mos 
post-intervention, while 
maintainers had a ↓ in 
HOMA baseline-12 mos 
post-intervention (p<.01) 
Trussardi Fayh 
et al. (2013)100 
Obese adults (BMI 
30-39.9 kg/m2, 22-
41 y), non-diabetic 
N=35 
Group 1: Dietary 
counseling for weight 
reduction (500-1000 
kcal/d reduction) 
Group 2: Dietary 
counseling + exercise 
Until participants lost 
5% of their initial weight 
Group 1: -4.5% post-
intervention 
Group 2: -4.8% 
Group 1: 19.5% ↓ in HOMA 
(p<.01) 
Group 2: 3.2% ↑ in HOMA 
(ns) 
 
DEXA, dual-energy x-ray absorptiometry; NGT, normal glucose tolerance; IFG, IGT, impaired glucose tolerance; FU, follow-up; HOMA, 
Homeostatic Model Assessment; IS, insulin sensitivity; VLCD, very low-calorie diet; T2D, type 2 diabetes; ns, non-significant; Ps, participants 
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Table 2-2 Description of pro- and anti-inflammatory cytokines associated with obesity and insulin resistance 
 
Cytokine 
 
Type/Description 
 
Source 
Health Effects Related to Obesity and the 
Insulin Resistance 
 
References 
IL-6 Pro-inflammatory, has 
some anti-inflammatory 
properties 
Several cells, including 
endothelial, smooth 
muscle, adipocytes, 
monocytes, and 
fibroblasts 
• Reduce glucose uptake  
• Associated with obesity 
• Increases TNF-α secretion 
 
103,107,110,203 
TNF-α Pro-inflammatory Mainly monocytes and 
macrophages; also 
includes adipocytes, 
macrophages, NK cells, 
and T cells  
• Associated with higher BMI and 
hyperinsulinemia 
• Inhibits adipogenesis 
• Increases lipolysis 
• Impairs insulin signaling  
 
103,131,132 
Adiponectin Anti-inflammatory; 
three forms (low-, 
medium-, and high-
molecular weight) 
Exclusively produced by 
adipose tissue 
• Negative correlation with adiposity 
• Insulin-sensitizing effects  
• Low levels associated with type 2 
diabetes 
• Can inhibit TNF-α and IL-6 and enhance 
production of anti-inflammatory 
cytokines 
 
131,203,204 
IL-10 Anti-inflammatory M2 macrophages and 
Th2 lymphocytes 
• Inhibits production of pro-inflammatory 
markers such as TNF-α and IL-6 
• Prevents atherosclerotic lesion 
development and stability 
• Shown to be both increased and 
decreased in obesity 
• May reduce IR through reduction in pro-
inflammatory cytokines 
 
89,145-149,152 
 
 
 
35 
 
 
Table 2-3 Weight loss studies examining the role of diet and exercise on cytokines among overweight/obese individuals 
Author 
(Year) 
 
Population 
Cytokine 
Studied 
 
Treatment 
Treatment 
Length 
Weight 
Change 
 
Findings 
Esposito et 
al. (2003b)139  
Obese, 
premenopausal 
women (BMI 30-49 
kg/m2, 20-46 y), 
non-diabetic 
N=120 
 
 
Adiponectin 
and IL-6 
Intervention group: detailed 
advice on achieving 
reduction in weight of ≥10%; 
education on calorie 
reduction, goal setting, self-
monitoring (3-d food diary) 
• 1300 kcal/d for 1styr; 
1500 kcal/d for 2ndyr 
Control group: general 
oral/written information 
about healthy food choices 
and exercise  
2 y At 2 y: 
 
Intervention: 
 -14.7% 
 
Control: -3.2% 
 
 
Mean % increase in adiponectin, 
baseline-2 y: 
• Intervention: 48.2% (p=.02) 
• Control: 9.3% (p=.13) 
 
Mean % decrease in IL-6, baseline-
2 y: 
• Intervention: -32.6% (p=.01) 
• Control: -7.3% (p=.15) 
Monzillo et 
al. (2003)130 
Obese (baseline 
BMI=36.7 kg/m2), 
adults (baseline 
age=49.3 y), 
various glucose 
tolerances (8 NGT, 
8 IGT, 8 T2D) 
N=24 
Adiponectin, 
TNF-α, IL-6 
Caloric restriction (low 
calorie, -500 kcal/d) and 
structured exercise (150 
min/wk at 60-80% of 
participant’s max heart rate)  
26 wks -7.0% (all 
glucose 
tolerance 
groups had a 
similar 
decrease in 
weight) 
4.3% increase in adiponectin 
(p=0.76), 17.4% ↓ in TNF-α 
(p=0.06), and a 14.8% ↓ in IL-6 
(p=0.01) after weight loss program; 
TNF-α sig. ↓ in the IGT group 
 (-28.6%, p=0.02) and adiponectin 
sig. ↑ in the T2D group (28.8%, 
p=0.01 
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Table 2-3 continued 
Author 
(Year) 
 
Population 
Cytokine 
Studied 
 
Treatment 
Treatment 
Length 
Weight 
Change 
 
Findings 
Ryan et al. 
(2003)154 
Overweight/obese 
postmenopausal 
women (BMI=32 
kg/m2, age =57 y), 
non-diabetic 
N=40 
Adiponectin Weight loss only (WL): 
• Calorie restriction 
 (-250-350 kcal/d) 
• Weekly weight loss 
classes 
 
WL+exercise (WL+EX): 
• Calorie restriction  
(-250-350 kcal/d) 
• Weekly weight loss 
classes 
• Supervised exercise 
3 times/wk 
 
WL+resistance training 
(WL+RT): 
• Calorie restriction  
(-250-350 kcal/d) 
• Weekly weight loss 
classes 
• Supervised 
resistance exercise 3 
times/wk 
6 mos -6.5% 
 
 
The total sample had a 5.8% ↑ in 
adiponectin at  6 mos (ns) 
Garaulet et 
al. (2004)141 
Obese women 
(baseline BMI=34 
kg/m2, age=37 y), 
non-diabetic 
N=33 
Adiponectin Liquid diet (~803 kcal/d) 4 wks Post-
intervention:  
-7.4%  
Non-significant 4% ↓ in adiponectin 
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Table 2-3 continued 
Author 
(Year) 
 
Population 
Cytokine 
Studied 
 
Treatment 
Treatment 
Length 
Weight 
Change 
 
Findings 
Manigrasso 
et al. 
(2005)149 
Android obese 
(BMI=39 kg/m2, 
age=47.2 y), and 
women, non-
diabetic 
N=15 
Adiponectin 
and IL-10 
Weight loss program (20-
25% fat, 1200 kcal/d); 
women encouraged to 
increase physical activity 
12 wks Median 8% 
decrease in 
BMI; 15.9% 
decrease in 
weight in 12 
women 
No significant change in 
adiponectin (1.0%, ns) or IL-10 
(7.3%, ns) 
Villareal et 
al. (2006)92 
Obese (baseline 
BMI=39 kg/m2), 
adults (baseline age 
~71 y), non-diabetic  
N=27 
IL-6 Control: usual diet and 
exercise routine 
 
Treatment: 750 kcal/d 
deficit, ~30% kcal from fat, 
goal of 10% weight loss; 
behavioral therapy 
26 wks Treatment 
group:    -8.2 
kg 
 
Control group: 
0.7 kg 
Compared to control group, 
treatment group had a greater 
decrease in IL-6 post-treatment  
(-30% vs. 48%, p<.001) 
Belza et al. 
(2009)140 
Obese adults 
(BMI=34 kg/m2, 
age 24-62 y), non-
diabetic 
N=33 
IL-6 Controlled intervention  
(all participants): 
Low-energy diet (LED-1): 
~812 kcal/d (1st 8 wks) 
M-1: weight maintenance 
 (4 wks) 
LED-2: ~1003 kcal/d  
(4 wks) 
M-2: weight maintenance  
(4 wks) 
Nutrition education 
20 wks After 20 wks: 
 -14.2%  
Compared to baseline, IL-6 
significantly reduced at end of 
study (-21%, p=.02) 
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Author 
(Year) 
 
Population 
Cytokine 
Studied 
 
Treatment 
Treatment 
Length 
Weight 
Change 
 
Findings 
Lien et al. 
(2009)61 
Adults 18 or older, 
BMI 30-50 kg/m2, 
w/o serious medical 
illnesses 
N=27 
Adiponectin, 
IL-6, IL-10, 
TNF-α 
Behavioral intervention 
• Reduced energy 
intake 
• Increased exercise 
• 20 weekly group 
sessions 
Those who lost ≥4 kg at 
initial weight loss 
randomized to: 
Group 1: personal phone 
counseling 
Group 2: interactive Web 
site 
Group 3: Control group 
6-mo weight 
loss period, 
followed by 6-
mo weight 
maintenance 
At 6 mos: 
 -6.3% 
At 12 mos: 
 -2.8% 
Weight regain 
from 6-12 mos: 
2.5% 
Adiponectin: 0.6% ↑ at 6 mos (ns); 
levels continued to ↑ at 12 (p=.03) 
 
IL-6: 21.9% ↓ at 6 mos (ns); slight 
↑ with weight regain at 12 mos (ns) 
 
IL-10: no significant changes over 
time 
 
TNF-α: no significant changes over 
time 
Ata et al. 
(2010)155 
Overweight/obese, 
adult 
premenopausal 
women (mean 
baseline BMI ~30 
kg/m2,age  20-45 y), 
non-diabetic 
N=70 
Adiponectin Weight loss intervention  
consisting of 30% protein, 
30% fat, and 40% 
carbohydrate and exercise 
using a pedometer, 
increasing steps by 1500 per 
week 
 
10 wks Post-
intervention: -
4.5% 
Adiponectin ↑ by 9.6% post-
intervention (p<.05) 
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Author 
(Year) 
 
Population 
Cytokine 
Studied 
 
Treatment 
Treatment 
Length 
Weight 
Change 
 
Findings 
Christiansen 
et al. 
(2010)138  
Obese adults (BMI 
30-<40 kg/m2, age 
18-45 y), 
Caucasian, non-
diabetic 
N=79 
Adiponectin Exercise only (EX): 
supervised exercise, 3 
times/wk, 60-75 min 
 
Hypocaloric diet (DI): liquid 
very-low calorie diet (600 
kcal/d) 
 
EX + DI: very-low calorie 
diet (800 kcal/d) + 
supervised exercise, 3 
times/wk, 60-75 min 
12 wks Post-
intervention: 
EX: -3.5%  
 
DI: -11% 
 
EX + DI: -11% 
Adiponectin post-intervention: 
 
EX: ↓ by 6% (ns) 
 
DI: ↑ by 19% (p<.01) 
 
EX + DI: ↑ by 20% (p<.01) 
Fisher et al. 
(2011)129 
Overweight 
premenopausal 
women (BMI=28 
kg/m2, age 20-41 y), 
non-diabetic 
N=126 
IL-6 and 
TNF-α 
Diet (D): 800 kcal/d 
 
Diet + exercise (D+E): 800 
kcal/d + 3 supervised 
sessions, ~50 min 
 
Diet + resistance training 
(D+R): 800 kcal/d + 3 
sessions/wk of 10 exercises 
related to resistance training 
4 wks Total weight 
loss:  
-15.4% 
 
By group: 
D: -15.4% 
D+E: -15.6% 
D+R: -15.4% 
Total reduction in cytokines: 
 IL-6: -26% (p=.001) 
TNF-α: -13.2% (p=.049) 
 
By group: 
D: IL-6 (-25.7%), TNF-α (-29.6%), 
p=.001 
 
D+E: IL-6 (-24.2%), TNF-α  
(-15.3%), p=.001 
 
D+R: IL-6 (-27.6%), TNF-α  
(-1.0%) 
 
IL-6 time effect: p=.001 
TNF-α time effect: p=.001 
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Author 
(Year) 
 
Population 
Cytokine 
Studied 
 
Treatment 
Treatment 
Length 
Weight 
Change 
 
Findings 
Lang et al. 
(2011)131 
 
Obese (BMI=30 
kg/m2, waist=100 
cm for women, 107 
cm for men) adults 
(age=40 y 
N=14  
 
Adiponectin 
and TNF-α 
Weight control program 
50 min exercise every 
Saturday 
Standard low-fat, low-calorie 
diet (3-day diet diary) 
8 wk -3.2%  Both adiponectin (ns) and TNF-α 
(ns) were higher after the 
intervention. No significant 
association between amount of 
weight loss and adiponectin or 
TNF-α  
Lira et al. 
(2011)156  
Obese adolescents 
(baseline BMI= ~35 
kg/m2, age=15 y), 
non-diabetic 
N=18 
Adiponectin, 
IL-6, IL-10, 
TNF-α 
Dietary and exercise 
intervention 
• Dietetics 
lessons, nutritional 
consultation 
• 60-min 
supervised sessions 
3 times/wk  
1 yr Post-
intervention:  
-11% 
Adiponectin ↑ by 33% post-
intervention (p<.001); ↑ in IL-10 
and a ↓ in IL-6 and TNF-α, all ns 
Rolland et al. 
(2011)157 
Obese (BMI≥35 
kg/m2) adults (18 
and older), non-
diabetic 
N=31 
Adiponectin, 
IL-6, TNF-α 
Low-calorie high-protein 
diet (LCHP):  
• 20% kcal 
carbohydrate, 40% kcal 
protein, 40% kcal fat 
• Energy intake: 800-
1500 kcal/d 
Very low-calorie diet (LL): 
• Meal replacements 
(soups, shakes, bars) 
• 550 kcal/d 
• 36% carbohydrate, 
36% protein, 28% fat 
• Group meetings 
(behavior change 
therapy) 
9 months At 9 mos: 
LCHP = -1.4% 
LL = -23.8%  
From baseline to 9 mos: 
 
Adiponectin ↑ by 77.8% in the LL 
group (p<.05) and ↓ by 3.2% in the 
LCHP group (ns) 
 
IL-6 remained the same in the LL 
group (baseline value=4.4 pg/mL) 
and ↓ by 13.8% in the LCHP group 
(from 2.9 to 2.5 pg/mL; ns) 
 
TNF-α ↑ by 4.7% in the LL group 
(ns), and by 2.0% in the LCHP 
group (ns) 
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Author 
(Year) 
 
Population 
Cytokine 
Studied 
 
Treatment 
Treatment 
Length 
Weight 
Change 
 
Findings 
Imayama et 
al. (2012)158 
Overweight/obese, 
postmenopausal 
women (baseline 
BMI ~31 kg/m2, 
mean baseline 
age~58 y), non-
diabetic 
N=438 
IL-6 Calorie restriction (CR): 
1200-2000 kcal/d, depending 
on weight, ≤30% kcal from 
fat; individual sessions with 
dietitian, group sessions 
 
Exercise (EX): moderate-to-
vigorous, 45 min/d, 5 d/wk 
 
CR+EX: both interventions  
 
Control: participants’ typical 
diet and exercise routine 
1 yr Weight loss at 
6 mos:  
CR: 6.6 kg 
EX: 1.0 kg 
CR+EX: 7.5 kg 
Control: 0.1 kg 
At 1 yr: 
 
Compared to control group, IL-6 
decreased by 4.5% for EX (p=.49), 
by 23.1% for CR (p=.001), and by 
24.3% for CR+EX (p<.0001) 
Tam et al. 
(2012)159 
Overweight adults 
(BMI= 27.8 kg/m2, 
age 25-<50 y), non-
diabetic 
N=35 
Adiponectin, 
IL-6, TNF-α 
Calorie restriction (CR): 
25% CR from baseline 
energy requirements 
 
CR + exercise (CR+EX): 
12.5% CR and 12.5% 
increase in exercise energy 
expenditure 
 
Control: healthy weight 
maintenance diet 
6 mos CR: -10% 
 
CR+EX: -10% 
 
Control: -1% 
CR: 
• 14% ↑ in adiponectin 
• 64% ↑ in TNF-α 
• 44% ↑ in IL-6 
 
CR+EX: 
• 7% ↑ in adiponectin 
• 79% ↑ in TNF-α 
• 5% ↑ in IL-6 
 
Control: 
• 6% ↑ in adiponectin 
• 44% ↑ in TNF-α 
• 9% ↑ in IL-6 
 
All results ns 
NGT, normal glucose tolerance; IGT, impaired glucose tolerance; T2D, type 2 diabetes; ns, non-significant p-value; HRT, hormone replacement 
therapy 
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Table 2-4 Description of cytokine gene polymorphisms and obesity-associated health outcomes 
Gene 
(Chromosome 
Location) 
 
 
SNP 
Polymorphim 
Location and 
Position 
 
Minor 
Allele 
 
Major 
Allele 
 
Minor Allele Associated 
with*: 
 
 
References 
Adiponectin (3q27) rs1501299  Intron 2 at 
+276 
T 
 
G 
 
• Reduced risk for CHD 
• Higher HDL levels 
• Lower triglyceride levels 
• Lower fasting insulin 
levels 
• Lower HOMA 
• Higher plasma 
adiponectin 
 
190,191,205-207 
rs266729  Promoter  
-11377 
G C • Both higher and lower 
plasma adiponectin 
• Higher HOMA-IR 
 
191,193,200 
TNF-α rs1800629  -308 A G 
 
• Higher fasting glucose 
levels 
• Increased type 2 diabetes 
risk 
• Higher risk of acute 
coronary syndrome 
• Increased TNF-α 
concentration 
 
30,40,208,209 
rs1800630 Promoter 
-863 
A C • Lower risk for type 2 
diabetes 
• Lower BMI and waist 
circumference 
• Higher TNF-α 
 
176,181 
IL-6 rs1800795  Promoter  
-174 
C G • Lower fasting glucose 
independent of BMI 
• Higher HOMA-IR 
• Increased IL-6 and BMI 
 
26,163,169,170 
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Gene 
(Chromosome 
Location) 
 
 
SNP 
Polymorphim 
Location and 
Position 
 
Minor 
Allele 
 
Major 
Allele 
 
Minor Allele Associated 
with*: 
 
 
References 
IL-10 rs1800896  
 
-1082 C T • Higher risk of acute 
coronary syndrome  
• Lower IL-10 
 
201,208 
rs1800871  -819 A G • Increased IL-10 
• Increased BMI in 
overweight/obese 
individuals 
 
35,201 
rs1800872  -592 (C/A) T G • Lower risk of acute 
coronary syndrome 
• Lower IL-10 
• Higher HOMA levels 
• Higher fasting insulin 
levels 
• Higher BMI 
 
34,208 
*compared to major allele carriers 
CHD, coronary heart disease 
 
 
 
 
 
 
Table 2-4 continued 
44 
3.0  LONGITUDINAL EFFECTS OF WEIGHT LOSS AND REGAIN ON CYTOKINE 
CONCENTRATION IN OBESE ADULTS 
Erica Joy Ambeba, MPH1,2; Mindi A. Styn, PhD1,2; Lewis H. Kuller, MD, DrPH2; Maria M. 
Brooks, PhD2,3; Rhobert W. Evans, PhD2; Lora E. Burke, PhD, MPH1,2 
1Department of Health and Community Systems, University of Pittsburgh School of Nursing, 
Pittsburgh, PA, USA 
2Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, 
Pittsburgh, PA, USA 
3Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, 
Pittsburgh, PA, USA 
(Manuscript Accepted for Publication by Metabolism Journal *) 
*Ambeba EJ, Styn MA, Kuller LH, Brooks MM, Evans RW, Burke LE. Longitudinal effects of
weight loss and regain on cytokine concentration in obese adults. Metabolism (2013), DOI: 
10.1016/j.metabol.2013.04.004. Accepted for publication April 3, 2013; online availability 
May 29, 2013.
45 
 
3.1 ABSTRACT 
Objective: To describe patterns of weight loss and regain and their effect on the pro-
inflammatory cytokines IL-6 and TNF-α, and anti-inflammatory cytokines adiponectin and IL-10 
during a 24-month weight loss trial. 
Methods: Participants were obese adults (N=66) who lost and regained ≥ 10 lbs during a 24-
month clinical trial of behavioral weight loss treatment. Measurements of cytokines and weight 
were conducted at baseline, 6, 12, 18, and 24 months. Linear mixed modeling was used to 
determine percent change in weight and cytokines from baseline.  
Results: The sample was predominantly female (80.3%) and White (86.4%), with a mean age of 
48.4±7.3 years and mean BMI of 34.5±4.4 kg/m2. At baseline, men had higher waist 
circumference, body weight, and energy intake, and lower percent body fat and adiponectin. The 
largest decrease in weight was observed at 6 months with a mean 11% decrease (p<.0001). A 
significant gender-by-weight change interaction on percent change in adiponectin was observed 
[b(se)=0.9 (0.2), p=.0003], with men having a larger increase in adiponectin with weight loss 
compared to women. There was a significant effect of weight gain over time with increases in 
IL-6 [b (se) = 0.9 (0.3), p=.001].  
Conclusion: Overall, weight loss was significantly associated with improvements in adiponectin 
and IL-6. Those improvements remained at 24 months, following weight regain. The association 
between weight change and adiponectin was different between genders. Implementing strategies 
that support sustained weight loss can help prevent a state of chronic systemic inflammation and 
its associated adverse effects.  
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3.2 INTRODUCTION 
Weight maintenance after intentional weight loss is difficult to achieve 210-212. Individuals 
may develop a pattern of repeated weight loss and regain, which can lead to the development of 
diabetes 213 and cardiovascular disease 77. However, there are inconsistencies in the literature 
regarding the effect of the cyclical pattern of weight loss and regain on an individual’s health.  
Adipose tissue is an active endocrine organ that produces and secretes pro-inflammatory 
cytokines (e.g., IL-6 and TNF-α,) and anti-inflammatory cytokines (e.g., adiponectin and IL-10). 
There is evidence that IL-6 and TNF-α are elevated in obese individuals and decrease with 
weight loss 214,215. In contrast, adiponectin and IL-10 are diminished in obese individuals and 
tend to increase with weight loss 150,216. Thus, obesity could be viewed as a chronic inflammatory 
state, characterized by a dysregulation in pro- and anti-inflammatory cytokines.  
There is limited literature on long-term weight cycling and cytokine expression. The 
purpose of our study was to describe the effect of weight cycling on multiple cytokines in a 
subset of participants who lost and regained at least 10 lbs during the 24-month SMART Trial, a 
behavioral weight loss study. This prospective study examined the association between changes 
in weight and changes in cytokines from baseline to 6, 12, 18, and 24 months. To the best of our 
knowledge, this is the first such report.  
 
47 
 
3.3 SUBJECTS AND METHODS 
3.3.1 Study Design 
The current study was a secondary analysis of data from the SMART Trial 
(NCT00277771), a single-centered, 24-month clinical trial of behavioral weight loss treatment 
that used a repeated measures design. The recruitment, screening, and enrollment details of the 
SMART Trial are published elsewhere217. Briefly, 210 participants were randomized to one of 
three conditions: 1) use of a standard paper diary; 2) use of an electronic diary with dietary and 
physical activity self-monitoring software; or 3) an electronic diary plus a customized feedback 
program for self-monitoring of diet and physical activity. The aim of the study was to determine 
whether self-monitoring of daily food intake and physical activity using a mobile device, with or 
without a daily, tailored feedback message, was superior to using a paper diary for short- and 
long-term weight loss.  
3.3.2 Participant Characteristics 
A sub-group of 66 SMART Trial (NCT00277771, 217) participants who lost and regained 
≥10 lbs at any time in the 24-month study were included in the analysis. Individuals were 
included if they were 18-59 years of age and had a BMI between 27 and 43 kg/m2. Detailed 
eligibility criteria were published elsewhere 217. Participants provided written informed consent; 
the study was approved by the University of Pittsburgh Institutional Review Board.  
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3.3.3 Intervention 
All participants received the standard behavioral intervention, which included: 1) self-
monitoring of diet and exercise; 2) group sessions; 3) daily energy and fat intake goals; and 4) 
weekly exercise goals.  
3.3.3.1 Self-monitoring 
Participants in the paper diary group were given standard paper diaries and instructed to 
record all foods eaten and the calorie and fat content (in grams), as well as minutes of exercise. 
Participants in the other two groups were provided a mobile device that contained dietary self-
monitoring software that tracked energy and fat intake and displayed on the screen of the device 
current intake related to daily goals; the software included a USDA-based, 6 000-item food 
database [DietMate Pro©218,219] and also software that permitted self-monitoring of physical 
activity (CalcuFit [PICS, Reston, VA]). At each session, paper diary participants submitted their 
diaries and received new ones to use until the next session. The interventionist reviewed those 
diaries, provided written feedback and returned the diaries at the next session. Participants in the 
other two groups turned in their mobile devices at the beginning of the session, the self-
monitoring data were uploaded to the study computer and the devices were returned to 
participants at the end of the session. The interventionists received printed reports that appeared 
similar to the standard paper diaries for their review. The reports with the interventionists’ 
written comments were returned to the participants at the next group session. In addition to the 
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feedback received on current energy and fat intake displayed on the screen of the mobile device 
next to the daily goals, the FB group received a daily message that reminded them to record, or if 
they had recorded, was responsive to the information they had entered. For example, if an 
individual was at risk for exceeding their energy goal at lunch but was within limits of their fat 
goal, a message would be delivered that read “Nice job limiting fats; might want to limit 
sweets/candy this afternoon.” While both groups received general feedback to the dairy at the 
next group session, the FB group received a daily message that was tailored to the diary entries 
made that day and delivered remotely in real time. 
3.3.3.2 Group sessions 
There were 39 group sessions, occurring weekly in months 1-4, bi-weekly in months 5-
12, and once a month in months 13-18. One session held during the final six months of the study 
focused on weight maintenance. Sessions included instructions in developing healthy eating and 
physical activity habits, group problem-solving exercises, and use of behavioral change 
strategies; they also provided practical hands-on experiences to develop skills related to 
implementing a healthy lifestyle. 
3.3.3.3 Dietary and exercise goals 
Each participant received a daily energy and fat gram goal based on her/his gender and 
baseline weight, consistent with standard behavioral weight loss treatment 210. The daily energy 
intake goal was between 1 200 and 1 500 calories for females and between 1 500 and 1 800 for 
males; the fat allowance was 25% of total calories for all participants. Participants were 
instructed to gradually develop an exercise program and aim to reach a weekly goal of 150 min 
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of moderate intensity exercise by the 6th week; the goal was increased by 30 minutes every six 
months. 
3.3.4 Measures 
A medical history form and sociodemographic data questionnaire were completed at 
baseline. Energy intake was measured in kilocalories per day (kcal/day) by two unannounced 24-
hour dietary recalls, conducted on one leisure day and one work day. A blood sample was 
obtained for total adiponectin, IL-10, IL-6, and TNF-α at baseline, 6, 12, 18, and 24 months. 
3.3.4.1 Anthropometric measurements 
Height was measured with a wall-mounted stadiometer and recorded in centimeters. 
Weight and percent body fat were measured following an overnight fast using a Tanita Scale and 
Body Fat Analyzer (Tanita Corporation of America, Inc., Arlington Heights, IL) while 
participants wore light clothing and stood erect with bare feet on the scale’s footpads.  
3.3.4.2 Cytokine measurements 
 TNF-α was measured by Luminex technology multiplex ELISA (Linco Research, Inc.; 
St. Charles, MO). The minimum detectable level (MDL) was 0.14 pg/mL, with an assay range of 
0.64-10,000 pg/mL. The intra- and inter-assay CVs were 1.4-7.9% and <21%, respectively. 
Quantitative sandwich enzyme immunoassay technique was used to measure IL-6 (Quantiglo 
Human IL-6 Immunoassay; R&D Systems, Minneapolis), with the MDL ranging from 0.05-0.35 
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pg/mL and an assay range of 0.48-1,500 pg/mL. The intra- and inter-assay CVs were 3.0-5.8% 
and 6.3-9.6%, respectively.  
IL-10 was measured by quantitative sandwich enzyme immunoassay technique 
(Quantikine HS Human IL-10 Immunoassay; R&D Systems, Minneapolis). The MDL was <0.5 
pg/mL, with an assay range of 0-50 pg/mL. The intra- and inter-assay CVs were 6.6-8.5% and 
8.1-15.6%, respectively. Finally, the ELISA technique was used for the adiponectin assay 
(Quantikine Human Adiponectin/Acrp30 Immunoassay; R&D Systems; Minneapolis), with a 
MDL of 0.25 ng/mL and intra- and inter-assay CVs of 2.5-4.7% and 5.8-6.9%, respectively All 
cytokine assays were performed at the Laboratory for Clinical Biochemistry Research at the 
University of Vermont. 
3.3.5 Data Analysis 
Summary statistics were reported as mean (SD) and frequency count (%). All non-normal 
weight and cytokine variables were log-transformed. Independent sample t-tests were used to 
compare baseline means between women and men. Spearman correlations were used to test the 
associations between baseline body weight and cytokines. Percent change from baseline to 6, 12, 
18 and 24 months were used in the analyses of weight and cytokines. Percent change from 
baseline was calculated as [(follow-up – baseline)/ baseline) x 100].  Linear mixed modeling was 
applied to assess the effects of weight change since baseline on change in cytokines from 
baseline, adjusting for time, age, race/ethnicity, gender, baseline body weight, baseline energy 
intake, baseline cytokine concentration, and percent change in energy intake. To determine 
whether associations between percent change in weight and percent change in cytokines varied 
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by gender, an interaction between gender and percent weight change was included in the models. 
In each cytokine model, a random intercept was used for each participant, and an unstructured 
covariance structure was assumed. P-values from the F-tests were reported.  In all analyses, the 
Bonferroni approach was used to correct for multiple testing (four tests: adjusted p=.0125). 
Analyses of the data were conducted using SAS version 9.2 (SAS Institute, Cary, NC) and IBM 
SPSS Statistics version 21.0 (IBM Corporation, Armonk, NY). 
3.4 RESULTS 
Baseline characteristics for women and men are displayed in Table 3-1. Participants’ 
mean age was 48.4 years. Compared to women, men had significantly higher weight, waist 
circumference, energy intake, and adiponectin, but significantly lower percent body fat.   
3.4.1 Associations between baseline weight and baseline cytokines 
Weight was significantly correlated with adiponectin (r = -.31, p=.01), IL-6 (r = .41, 
p=.001), and TNF-α (r = .43, p<.0001), but there was no significant correlation between IL-10 
and weight (r = .05, p=.68). There were significant correlations between cytokines, including 
adiponectin and IL-6   (r = -.33, p=.01), adiponectin and TNF-α (r = -.31, p=.01), and IL-6 and 
TNF-α (r = .25, p=.04). There were no significant associations between IL-10 and the other 
cytokines.  
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3.4.2 Description of percent change in weight and cytokines by time 
Description of the percent changes in weight and cytokines over time are displayed in 
Figure 3-1. The largest decrease in weight was observed at 6 months (-11%, p<.0001), with 
evidence of regain at 12, 18, and 24 months. Concurrent with baseline to 6-month weight loss, 
adiponectin increased by 13.4% (p<.0001). From baseline to 12 months, adiponectin 
significantly increased by 23.8% (p<.0001), while IL-6 significantly decreased from baseline 
(-18.1%, p=.0003). Baseline to 18-month changes were significant only for adiponectin (19.1%, 
p=.0001); at 24 months, adiponectin was significantly higher than at baseline (9.9%, p=.004) but 
was lower than the 18-month values. There were no significant changes in IL-10 or TNF-α at 
either time points. 
3.4.3 The associations between percent change in weight and percent changes in cytokines 
Linear mixed models results on the associations between percent change in weight and in 
cytokines are shown in Table 3-3. Controlling for covariates, a significant interaction between 
gender and percent change in weight on percent change in adiponectin over time was detected 
[b(se)=0.9 (0.2), p=.0003], with men having a higher percent increase in adiponectin with weight 
loss, compared to women with the same amount of weight loss (Figure 3-2). For example, if men 
had an overall weight loss of 20%, they increased their adiponectin concentration by about 20%; 
however, women with the same amount of weight loss only increased their adiponectin 
concentration by about 10%. The opposite was true for weight regain; compared to women, men 
had greater decreases in adiponectin with the same amount of weight regain. Change in weight 
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was significantly associated with change in IL-6 [b(se)=0.9 (0.3), p=.001], and marginally 
associated with change in IL-10 [b(se)=0.3 (0.2), p=.07]. There was no significant association 
between weight changes and TNF-α changes [b(se)=-0.1 (0.1), p=.22]. 
3.5 DISCUSSION 
We observed improvements in cytokines after weight loss, and despite participants 
regaining most of their lost weight by 24 months, improvements in cytokines persisted. 
Moreover, we demonstrated that decreases in weight predicted an increase in adiponectin and a 
decrease in IL-6.  We also showed that the association between weight change and change in 
adiponectin was different for men and women. Although there were significant associations 
between weight and adiponectin, IL-6, TNF-α at baseline, only adiponectin was significantly 
associated with weight loss, and an 11% weight loss led to a significant increase in adiponectin.  
Because adiponectin is exclusively released from adipose tissue, it may be more sensitive to the 
hypertrophic changes in adipocytes. Conversely, IL-6, TNF-α, and IL-10 originate from a variety 
of sources, which can affect serum expression of cytokines during weight changes. Although the 
weight-loss associated increases in adiponectin have been well-described143,144,155,220,221, there are 
inconsistencies regarding changes in the other cytokines with weight loss. Sofer et al. found IL-6 
significantly decreased at 6 months of weight loss treatment but did not find any significant 
changes in TNF-α 222. In contrast, Pakiz et al. found that TNF-α significantly decreased with 
weight loss with no significant changes in IL-6 223. Methodological differences among these 
studies may have contributed to the variability of the results.  
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We observed continued improvements in cytokines from the 6-month point, 
demonstrating that the improved cytokine concentration occurring with weight loss can be 
sustained despite weight regain. This suggests a delayed effect of weight regain on cytokine 
concentration. At 24 months, adiponectin declined and IL-6 increased from the point of greatest 
weight loss, suggesting that regain attenuates the effects of weight loss on some cytokines. Our 
findings that improvements in cytokines persist despite weight regain support similar findings 
reported by others 61,144. However, Erez et al. found a positive association between adiponectin 
and weight loss but no significant association between adiponectin and weight regain 143.  
  Baseline correlation did not reveal significant associations between IL-10 and 
adiposity measures or other cytokines. There is evidence that IL-10 is reduced in obese states 149. 
However, the evidence on IL-10 and weight change is limited, making this association unclear. 
We noticed that men had greater increases in adiponectin with weight loss than women, despite 
both groups having the same amount of weight loss. We also noticed that men had greater 
decreases in adiponectin with regain than women, despite both groups having the same amount 
of regain. This suggests that weight loss studies should target men, as they may have great health 
benefits from weight loss.  
The only study similar to ours was conducted by Lien et al. who described changes 
following a 6-month behavioral weight loss intervention followed by weight regain 61. They did 
not observe a significant change in adiponectin levels concurrent with the weight loss, nor did 
they observe any significant changes in IL-6 during weight loss or regain. However, they 
observed an increase in adiponectin from baseline to post-weight regain, also showing the 
sustained improvement in adiponectin despite weight regain 61.  
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Bluher et al. examined cytokines in participants enrolled in a study of Mediterranean diet 
vs. low carbohydrate diet 144 and demonstrated an increase in adiponectin with weight loss; 
however, there was a continued increase in adiponectin levels at 24 months. There are several 
differences between Bluher et al.’s and the current study. First, Bluher et al. included participants 
with type 2 diabetes, those with varying weight change patterns (e.g. maintained, lost or regained 
weight), and did not restrict energy intake whereas our study recommended a restricted calorie 
and 25% fat eating plan. Additionally, women represented 14% of their sample while 80% of our 
participants were women. Lastly, Bluher et al. used a trend analysis that precluded them from 
determining whether the association between weight change and change in cytokines was 
statistically significant 144. It is possible that failing to control for part of the sample that 
maintained their weight may have contributed to the observed increase in adiponectin at 24 
months in Bluher et al.’s study. Limiting the sample to only participants who lost and regained 
weight precludes the occurrence of bias that may occur when including individuals who 
maintained the weight loss.  
Regarding study limitations, we did not have a control group with which to compare our 
results. Although we found significant associations between changes in weight and changes in 
cytokines, we cannot make any causal inference. We included healthy individuals within specific 
ages and BMIs, thus our results cannot be generalized to dissimilar populations. Our study also 
has several strengths. We studied a unique population of individuals who lost and regained ≥10 
lbs and also incorporated a longitudinal study design with data collected at five time points over 
two years.  In summary, changes in weight were associated with changes in adiponectin and IL-
6. The improvement in these cytokines persisted even with nearly total weight regain, suggesting 
that weight loss can have protective effects despite weight regain. Because the majority of 
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individuals who lose weight experience weight regain, it is important to develop strategies to 
prevent regain to reduce the duration of exposure to an inflammatory state, thus reducing the risk 
of developing chronic diseases such as diabetes and atherosclerosis.  
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Table 3-1 Mean (SD) baseline characteristics of the participants 
 
Characteristic 
Women 
(n=53) 
Men 
(n=13) 
Total 
(N=66) 
Age (years) 47.6 (7.3) 51.5 (7.2) 48.4 (7.4) 
Weight (kg)* 92.8 (13.7) 111.9 (14.3) 96.5 (15.7) 
BMI (kg/m2) 34.3 (4.3) 35.4 (4.6) 34.5 (4.4) 
Waist (cm)* 105.1 (12.3) 119.3 (11.4) 107.9 (13.3) 
Energy intake (kcal/day)* 2029 (480) 2781 (696) 2177 (604) 
Body Fat Composition (%)* 44.0 (4.5) 33.9 (5.3) 42.0 (6.1) 
Adiponectin (µg/mL)* 18.2 (9.5) 11.6 (5.2) 16.9 (9.2) 
IL-10 (pg/mL) 8.8 (4.3) 8.7 (3.6) 8.8 (4.1) 
IL-6 (pg/mL) 2.5 (1.4) 2.8 (1.7) 2.6 (1.5) 
TNF-α (pg/mL) 5.0 (4.8) 5.5 (1.7) 5.1 (4.3) 
kg=kilograms; kg/m2=kilograms per square meters; cm=centimeters; kcal/day=kilocalories per 
day; MET-h/wk=metabolic equivalent of task-hours per week; μg/mL=micrograms per deciliter; 
pg/mL=picograms per deciliter 
*p<.05 women vs. men from t-tests 
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Table 3-2 Description of percent change in weight and cytokines from baseline to 6, 12, 18, 
and 24 months 
 
Characteristic 
 
6 months 
 
12 months 
 
18 months 
 
24 months 
 Mean (SE1) Mean (SE1) Mean (SE1) Mean (SE1) 
Weight -10.7 (0.6)* -9.6 (0.9)* -5.1 (0.9)* -3.3 (0.8)* 
Adiponectin 13.4 (2.9)* 23.8 (4.4)* 19.1 (4.7)* 9.9 (3.3)* 
IL-10  2.5 (4.8) 8.8 (5.1) 4.8 (5.3) 12.4 (10.8) 
IL-6 -7.7 (4.5) -18.1 (4.8)* -4.6 (5.0) -1.1 (9.2) 
TNF-α  -5.6 (4.7) -4.2 (6.9) -3.6 (4.9) 0.4 (6.3) 
1standard error 
*significant difference from baseline (p<.05) 
Results are least squares means  
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The red line represents mean percent change in: a. adiponectin; b. IL-10; c. IL-6; and d. TNF-α. 
The blue line represents mean percent change in weight. Results are least squares means and 
standard errors from linear mixed models.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1 Description of percent change in weight and percent change in cytokines 
over time (N=66) 
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Figure 3-2 Scatterplot of the interaction between gender and percent weight change on 
percent change in adiponectin over time 
Note: The scatterplot represents multiple time points per individual  
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Table 3-3 Percent change in cytokines over time for every percent change in weight (N=66)1 
 
Cytokine2 
 
B 
 
SE 
 
P 
     
Adiponectin  -2.2 0.5 <.0001  
IL-10  0.3 0.2 .07  
IL-6 0.9 0.3 .0001  
TNF-α  -0.1 0.1 .22  
1Models adjusted for time, age, race/ethnicity, gender, baseline weight, baseline energy intake, 
baseline log-transformed cytokine concentration (either adiponectin, IL-10, IL-6, or TNF-α, 
depending on the outcome), and percent change in energy intake 
2Percent change in log-transformed cytokine 
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4.1 ABSTRACT 
Background: Obesity is linked to the development of insulin resistance (IR) and type 2 diabetes. 
Weight loss achieved by lifestyle modification could improve insulin sensitivity. However, 
weight loss is difficult to maintain, and individuals often weight cycle, potentially placing them 
at greater risk for adverse health outcomes. 
Objective: The purpose of this secondary analysis was to examine how long-term changes in 
weight are associated with changes in factors related to the development of diabetes (insulin 
concentration and IR) among obese adults enrolled in a 24-month behavioral weight loss trial. 
Methods: The sample (N=66) included non-diabetic adults who lost and regained at least 10 lbs 
during the 24-month trial. All participants received standard behavioral weight loss treatment 
during the first 18 months. Assessments were conducted at baseline, 6, 12, 18, and 24 months. IR 
was assessed using the homeostatic model assessment (HOMA-IR). Linear mixed modeling was 
used to examine the association between % changes in weight and % changes in fasting insulin, 
and HOMA-IR. All models were adjusted for time, age, gender, race, baseline weight, and 
baseline metabolic measure. 
Results: The sample was 80% female and 86% White. At baseline, the mean (±SD) values were: 
age, 48.4±7.4 years; BMI, 34.5±4.4 kg/m2; plasma insulin, 16.9±6.0 μU/mL; fasting glucose, 
96.6±8.8 mg/dL; and HOMA-IR, 4.1±1.7. On average, compared to baseline, participants 
experienced an 11% decrease in weight (p<.0001), a 9% decrease in insulin (p=.004), and a 10% 
decrease in HOMA-IR (p=.01) at 6 months. Following 6-month weight loss, an average of 8.4% 
of baseline weight was regained by 24 months (p<.0001), and the positive changes observed in 
the other measures were partially reversed, e.g., a 19% increase in insulin (p=.001), and a 26% 
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increase in HOMA (p=.001). Overall, weight change was positively associated with changes in 
insulin [b(se)=0.5(0.1), p≤.0001] and HOMA [b(se)=0.8(0.2), p≤.0001]. 
Conclusion: In this sample of participants who weight cycled during a 24-month trial, weight 
loss improved metabolic outcomes; however, this was attenuated when weight was regained. 
These results reveal the effects of changes in weight on metabolic outcomes and highlight the 
importance of sustaining healthy lifestyle changes that support weight loss maintenance and 
improved metabolic outcomes.  
4.2 INTRODUCTION 
Obesity has become one of the most prevalent health issues. The global prevalence of 
obesity is approximately 500 million, and by 2015, it is expected to reach approximately 700 
million45. Currently in the U.S., about 36% of adults are obese1, and the current obesity epidemic 
is partly responsible for the increase in diseases such as hypertension, diabetes, and the metabolic 
syndrome49. Insulin resistance (IR), characterized by reduced glucose uptake in targeted 
peripheral tissues4, is present in obesity and is considered a mediator in the obesity-type 2 
diabetes pathway.  
Lifestyle modification, consisting of decreased energy intake, increased energy 
expenditure, and behavioral modification, is considered the cornerstone to weight loss 
treatment6. Currently, about 57% of women and 40% of men are attempting to lose weight9, and 
moderate weight loss of about 5-10% of initial weight is associated with improvements in 
obesity-associated comorbidities8. Often, individuals succeed in short-term weight loss; however, 
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long-term weight maintenance is difficult to achieve58, and many individuals who intentionally 
lose weight often regain all or part of the lost weight within 1-5 years post-weight loss56,57,60. 
These individuals can enter into a pattern of weight loss and regain, or weight cycling, which can 
have detrimental health effects.  
Although modest weight loss can improve health outcomes such as IR, it is unclear 
whether these improvements remain or are attenuated when weight is regained61. Very few 
studies have addressed the effect of weight regain on IR. Of the studies that have addressed this 
issue, the results have been mixed. Some studies have found a significant association75, while 
other studies have not76,77. Many of these studies are limited because of short duration of weight 
loss intervention, measuring individuals at only one or two time points, cross-sectional rather 
than longitudinal studies, inclusion of both unintentional and intentional weight loss78, and lack 
of detail regarding amount and timing of weight regain76,78. Therefore, the purpose of this study 
is to describe the effect of weight cycling on metabolic variables in a subset of participants who 
lost and regained at least 10 lbs during the 24-month SMART Trial, a behavioral weight loss 
study. This prospective study examined the association between changes in weight and changes 
in insulin, glucose, IR, and insulin sensitivity (IS) across four time periods: from baseline to 6, 
12, 18, and 24 months.  
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4.3 METHODS 
4.3.1 Study Design 
The current study was a secondary analysis of data from the SMART Trial 
(NCT00277771), a single-centered, 24-month clinical trial of behavioral weight loss treatment 
that used a repeated measures design. Details of recruitment, screening, and enrollment are 
outlined elsewhere217. Briefly, 210 individuals were randomized to one of three conditions: 1) 
use of a standard paper diary; 2) use of an electronic diary with dietary and physical activity self-
monitoring software; or 3) an electronic diary plus customized feedback program for self-
monitoring of diet and physical activity. The aim of the study was to determine whether self-
monitoring of daily food intake and physical activity using a mobile device, with or without a 
daily, tailored feedback message, was superior to using a paper diary for short- and long-term 
weight loss.  
4.3.2 Participant Characteristics 
A total of 66 SMART Trial subjects who lost ≥10 lbs of body weight and later regained ≥ 
10 lbs were included in the analysis. The weight loss and regain occurred at any time in the 24-
month study. Individuals were eligible for inclusion in the parent study if they were 18-59 years 
of age with a BMI between 27 and 43 kg/m2, were willing to be randomized to one of the three 
treatment conditions, and had completed five-day recording of food intake in a paper diary. 
Individuals were excluded from the study if they had physical limitations that prohibited their 
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ability to exercise; reported alcohol intake of ≥4 drinks/day; presented with an eating disorder; 
participated in a weight loss program or used of weight loss medication within the 6 months prior 
to enrollment; planned an extended vacation, absence, or relocation during the study, were 
pregnant or planning to become pregnant during the study; and had a current serious illness or 
unstable condition requiring physician-supervised diet and exercise, including a glucose level 
above 125 mg/dL at baseline. All participants provided written informed consent, and the study 
protocol was approved by the University of Pittsburgh Institutional Review Board. 
4.3.3 Intervention 
All participants received the standard behavioral intervention, which included: 1) self-
monitoring of diet and exercise; 2) group sessions; 3) daily energy and fat intake goals; and 4) 
weekly exercise goals.  
4.3.3.1 Self-monitoring 
Participants in the paper diary group were given standard paper diaries and instructed to 
record all foods eaten and the calorie and fat content (in grams), as well as minutes of exercise. 
Participants in the other two groups were provided a mobile device that contained dietary self-
monitoring software that tracked energy and fat intake and displayed on the screen of the device 
current intake related to daily goals; the software included a USDA-based, 6000-item food 
database [DietMate Pro©218,219] and also software that permitted self-monitoring of physical 
activity (CalcuFit [PICS, Reston, VA]). At each session, paper diary participants submitted their 
diaries and received new ones to use until the next session. The interventionist reviewed those 
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diaries, provided written feedback and returned the diaries at the next session. Participants in the 
other two groups turned in their mobile devices at the beginning of the session, the self-
monitoring data were uploaded to the study computer and the devices were returned to 
participants at the end of the session. The interventionists received printed reports that appeared 
similar to the standard paper diaries for their review. The reports with the interventionists’ 
written comments were returned to the participants at the next group session. 
4.3.3.2 Dietary and exercise goals 
Each participant received a daily energy and fat gram goal based on her/his gender and 
baseline weight, consistent with standard behavioral weight loss treatment210. The daily energy 
intake goal was between 1200 and 1500 calories for females and between 1500 and 1800 for 
males; the fat allowance was 25% of total calories for all participants. Participants were 
instructed to gradually develop an exercise program and aim to reach a weekly goal of 150 min 
of moderate intensity exercise by the 6th week; the goal was increased by 30 minutes every six 
months. 
4.3.3.3 Group sessions 
There were 39 group sessions, occurring weekly in months 1-4, bi-weekly in months 5-
12, and once a month in months 13-18. One session held during the final six months of the study 
focused on weight maintenance. Sessions included instructions in developing healthy eating and 
physical activity habits, group problem-solving exercises, and use of behavioral change 
strategies; they also provided practical hands-on experiences to develop skills related to 
implementing a healthy lifestyle. 
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4.3.3.4 Feedback 
In addition to the feedback received on current energy and fat intake displayed on the 
screen of the mobile device next to the daily goals, the FB group received a daily message that 
reminded them to record, or if they had recorded, was responsive to the information they had 
entered. For example, if an individual was at risk for exceeding their energy goal at lunch but 
was within limits of their fat goal, a message would be delivered that read “Nice job limiting 
fats; might want to limit sweets/candy this afternoon.” While both groups received general 
feedback to the dairy at the next group session, the FB group received a daily message that was 
tailored to the diary entries made that day and delivered remotely in real time. 
4.3.4 Measures 
Height was measured with a wall-mounted stadiometer and recorded in centimeters. 
Weight and percent body fat were measured following an overnight fast using a Tanita Scale and 
Body Fat Analyzer (Tanita Corporation of America, Inc., Arlington Heights, IL) while 
participants wore light clothing and stood erect with bare feet on the scale’s footpads. Blood 
samples were obtained for assessment of insulin and glucose levels, and both metabolic measures 
were analyzed at the University of Pittsburgh Graduate School of Public Health’s Chemistry and 
Nutrition Laboratory. Insulin was measured using a radioimmunoassay procedure developed by 
Linco Research, Inc. Glucose samples were quantitatively determined by an enzymatic method 
described by Bondar and Mead (1974)224. The coefficient of variation (CV) for insulin was 8.2 
+/- 0.7 (170) %) and was 2.0% for glucose. The intra-assay CVs for insulin and glucose were 
7.0% and 1.6%, respectively. Insulin resistance was assessed by the Homeostatic Model 
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Assessment of Insulin Resistance (HOMA-IR), calculated as [fasting insulin (μU/mL) x fasting 
glucose (mg/dL)] / 405.  
4.3.5 Data Analysis 
Descriptive statistics were calculated as mean (standard deviation) for continuous 
variables and proportions for categorical variables. Variables were assessed for normality, and 
non-normal variables were log-transformed. Simple linear regression was used to determine 
whether covariates were associated with baseline insulin and HOMA-IR. Covariates included 
were age, race, gender, and baseline: BMI, weight, waist circumference, metabolic variables, 
energy intake, adiponectin, IL-6, IL-10, and TNF-α. If covariates had a p<.10, they were 
examined as part of the multivariable regression model. Any covariates that were statistically 
significant at p<.10 from the multivariable model were covariates used for the linear mixed 
model analyses. Percent change from baseline to 6, 12, 18 and 24 months were used in the 
analyses of weight and cytokines. Percent change from the study entry time point was calculated 
as [(follow-up – baseline)/ baseline) x 100].  Linear mixed modeling with linear contrasts was 
applied to assess the effects of weight change since baseline on changes in insulin and HOMA-
IR from baseline. The models were adjusted for age; race; gender; baseline: BMI, weight, insulin 
or HOMA-IR, and energy intake; and percent change in energy intake. The interaction between 
gender and percent change in weight was also tested and dropped from the model if not 
significant. In each metabolic model, a random intercept was used for each participant, and an 
unstructured covariance structure was assumed. P-values from the F-tests were reported.  In all 
analyses, the significance level was set at p = 0.05 for two-sided hypothesis testing.  Analyses of 
72 
 
the data were conducted using SAS version 9.2 (SAS Institute, Cary, NC) and IBM SPSS 
Statistics version 21.0 (IBM Corporation, Armonk, NY). 
4.4 RESULTS 
Baseline demographic, anthropometric, and clinical characteristics of the participants 
(N=66) are shown in Table 4-1. The majority of participants were middle-aged (48.4±7.4 years), 
female (80%), White (86.4%), and educated (16.1±3.2 years). Compared with women, men had 
significantly higher body weight, waist circumference, insulin, fasting glucose, and HOMA-IR, 
but significantly lower percent body fat. 
4.4.1 Description of percent change in weight and metabolic measures over time 
Percent changes in weight and metabolic measures from baseline to 6, 12, 18, and 24 
months are outlined in Table 4-2 and Figures 4-1 and 4-2. On average, participants lost 
approximately 11% of their baseline body weight at 6 months (p<.0001), and there was evidence 
of regain at 12, 18, and 24 months. Concurrent with baseline to 6-month weight loss, there were 
positive changes in insulin and HOMA-IR. Specifically, there were decreases in insulin (-8.9%, 
p=.004) and HOMA-IR (-9.6%, p=.01) from baseline to 6 months.  By 24 months, improvements 
in metabolic measures were not sustained. Specifically, there were 5% and 8% increases in 
insulin and HOMA-IR, respectively, from baseline to 24 months. However, none of these 
changes at 24 months were significant.  
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4.4.2 The associations between percent change in weight and percent changes in 
metabolic measures 
Table 4-3 outlines results of linear mixed models examining the association between 
percent changes in weight and metabolic measures over time, controlling for time, age, race, 
gender, and baseline weight and metabolic measures. Change in weight was significantly 
associated with insulin [b(se)=0.5(0.1), p≤.0001] and HOMA-IR [b(se)=0.8(0.2), p≤.0001]. 
Specifically, weight loss was associated with a 0.5% decrease in insulin (p≤.0001) and a 0.8% 
decrease in HOMA-IR (p≤.0001).  
4.5 DISCUSSION 
In this secondary analysis of a 2-year behavioral weight loss intervention trial of 
participants who lost and regained ≥10 lbs, we observed decreases in metabolic measures with 
moderate weight loss. However, with nearly total weight regain at 24 months, these 
improvements were not sustained. Moreover, we found that decreases in weight predicted 
decreases in insulin concentration and HOMA-IR. Our findings of improved metabolic measures 
after moderate intentional weight loss are supported by the literature. A 6-month weight loss 
study by Antuna-Puente et al. found that, with a 6% decrease in BMI, HOMA-IR and fasting 
insulin concentration each significantly decreased by 12%225. Likewise, a study by Rector et al. 
found a calorie-restricted and moderate-intensity exercise program that produced a 9% weight 
loss at 6 months decreased HOMA-IR by 28%226. 
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Although there is a general consensus in the literature that weight loss improves 
metabolic measures, there is inconsistency on the role of weight regain in metabolic outcomes. 
Very few studies have investigated the effect of weight regain after intentional weight loss on 
metabolic measures. Lien et al.61 discovered that, in obese adults who lost 6% of their initial 
body weight at 6 months of a behavioral weight loss intervention, HOMA-IR and insulin were 
significantly lower at end of study (12 months) compared to baseline, despite the weight regain. 
Unlike Lien et al., we did not observe persistent metabolic improvement during weight regain. 
This may be due to participants in Lien et al.’s study having partial weight regain at 12 months, 
whereas participants in our study had nearly total regain at 24 months. Also, Lien et al.’s study 
was one year long; it is possible that if they had followed their participants for 2 years, they may 
have seen higher insulin concentration and HOMA-IR at conclusion of the study.  
When investigating differences in insulin and HOMA-IR from baseline to each time 
point, we observed a 9% and 10% decrease in insulin and HOMA-IR, respectively, at 6 months, 
corresponding with the 11% decrease in weight. With weight regain at 24 months, we observed a 
5% and 8% increase in insulin and HOMA-IR, respectively. However, results were only 
significant during the weight loss period. Beavers et al.99 investigated changes in cardiometabolic 
outcomes among participants in a weight loss intervention. As with our study, they found change 
in weight to be significantly associated with change in HOMA-IR, and that HOMA-IR was 
adversely affected by weight regain. Authors demonstrated that the magnitude of improvement 
in metabolic measures was most pronounced during the weight loss phase, rather than regain 
phase. Other studies72,227 also show similar results. It may be that changes in insulin and HOMA-
IR are more sensitive during a period of weight loss but not during weight regain. Or, this may 
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point to variability in factors associated with weight regain, such as behavioral, environmental, 
genetic, clinical, and molecular factors228.  
There are some limitations to our study that need to be addressed. First, we do not have 
any control groups with which to compare our results. Second, although we found significant 
associations between changes in weight and changes in metabolic measures, we cannot make any 
causal inference. We also used HOMA-IR as a measure for IR, and we acknowledge that there 
are caveats when using quantitative measures of IR. Nevertheless, HOMA-IR has been shown to 
be a good measure in the early detection of the development of type 2 diabetes229, and has been 
well-validated when compared to the hyperinsulinemic euglycemic clamp, and is particularly 
effective in non-diabetic, insulin resistant populations230. Finally, because we included healthy 
individuals within specific ages and BMIs, our results cannot be generalized to populations 
outside of our age and BMI ranges or populations with chronic health issues. Our study also has 
several strengths. First, we have a unique population of individuals who lost and regained ≥10 
lbs. We also incorporated a longitudinal study design with data collected at five time points over 
the course of two years. This is in contrast to the majority of studies that are either cross-
sectional or collected data at only one or two follow-up points. We had a sample that was diverse 
by race and gender. 
In conclusion, moderate weight loss was associated with significant improvements in 
metabolic measures. During weight regain, improvements in metabolic measures were not 
sustained. Strategies are needed to circumvent weight regain in order to maintain a healthy 
metabolic profile, preventing diseases such as type 2 diabetes and cardiovascular disease.  
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Table 4-1 Baseline sociodemographic and clinical characteristics of the participants 
 
Characteristic 
Men 
(n=13) 
Women 
(n=53) 
Total 
(N=66) 
Age (years) 51.5 (7.2) 47.6 (7.3) 48.4 (7.4) 
BMI (kg/m2) 35.4 (4.6) 34.3 (4.3) 34.5 (4.4) 
Education (years) 16.2 (3.7) 16.1 (3.1) 16.1 (3.2) 
Weight (kg)* 111.9 (14.3) 92.8 (13.7) 96.5 (15.7) 
Waist Circumference (cm) * 119.3 (11.4) 105.1 (12.3) 107.9 (13.3) 
Body Composition (%)* 33.9 (5.3) 44.0 (4.5) 42.0 (6.1) 
Insulin (μU/mL) * 21.6 (8.1) 15.8 (4.9) 16.9 (6.0) 
Glucose (mg/dL) * 101.7 (6.1) 95.5 (9.0) 96.6 (8.8) 
HOMA-IR* 5.4 (2.1) 3.8 (1.5) 4.1 (1.7) 
Mean (SD) 
*p<.05 between groups (t-test results) 
 
Table 4-2 Percent change in weight and metabolic measures from baseline to 6, 12, 18, and 
24 months (N=66)1 
 
Characteristic 
 
6 months 
 
12 months 
 
18 months 
 
24 months 
 Mean (SE2) Mean (SE2) Mean (SE2) Mean (SE2) 
Weight -10.7 (0.6)* -9.6 (0.9)* -5.1 (0.9)* -3.3 (0.8)* 
Insulin -8.9 (2.9)* -6.3 (3.1)* -1.2 (3.2) 4.9 (4.3) 
HOMA-IR  -9.6 (3.3)* -8.2 (3.7)* 0.6 (3.9) 8.4 (5.5) 
1 Results are least squares means from linear mixed models with time effect 
2standard error 
*significant difference from baseline (p<.05; p-values from F tests) 
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Figure 4-1 Percent changes in weight and insulin over time (N=66) 
*p<.05 at respective time points 
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Figure 4-2 Percent changes in weight and HOMA-IR over time (N=66) 
*p<.05 at respective time points 
 
Table 4-3 Linear mixed modeling of percent changes in metabolic measures over time for 
every percent change in weight1 
 
Characteristic2 
 
β 
 
SE3 
 
P4 
Insulin 0.5 0.1 <.0001 
HOMA-IR 0.8 0.2 <.0001 
1Adjusted for time, age, race, gender, baseline weight, baseline energy intake, percent change in 
energy intake, and baseline log-transformed insulin or HOMA-IR 
2Log-transformed 
3standard error 
4P-values are from F-tests 
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5.1 ABSTRACT 
Background: Abnormal cytokine secretion is partly responsible for obesity-associated 
complications such as insulin resistance (IR). Single-nucleotide polymorphisms (SNPs) in 
cytokine genes may be associated with IR. Whether SNPs influence changes in metabolic risk 
factors during weight loss treatment and weight regain is underexplored. 
Objectives: To determine whether SNPs in genes encoding IL-6, TNF-α, adiponectin, and IL-10 
are associated with changes in cytokine concentration and IR among obese adults who lost and 
regained ≥ 10 lbs. 
Methods: Eight SNPs in four cytokine genes (ADIPOQ: rs1501299, rs266729; IL-10: 
rs1800896, rs1800871, rs1800872; IL-6: rs1800795; and TNF-α: rs1800629, rs1800630) were 
genotyped in 65 participants (mean BMI=34.6±4.3 kg/m2) from the SMART Trial, a 24-month 
clinical trial of weight loss treatment. IR was evaluated using the homeostatic model assessment 
(HOMA-IR). Multiple linear regression was used to examine the association between each SNP 
and baseline changes in cytokines and HOMA-IR, controlling for age, ethnicity, gender, baseline 
weight, and for HOMA-IR, baseline adiponectin and TNF-α. Linear mixed models examined the 
association between each SNP and percent change in cytokine and HOMA-IR from baseline. For 
SNPs, a dominant model was used. All SNPs were in Hardy-Weinberg equilibrium.  
Results: Compared with individuals with the TT genotype, variant allele C carriers for 
rs1800896 had higher baseline HOMA-IR [b(se)=1.0 (0.4), p=0.02]. Compared with individuals 
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homozygous for the major allele, carriers of minor alleles A and T for rs1800871 and rs1800872, 
respectively, had lower baseline HOMA-IR [for both SNPs: b(se)=-1.2 (0.4), p=.01]. There were 
no significant associations between SNP and either percent change in cytokine concentration or 
percent change in HOMA-IR over time. No significant interactions between SNP and weight 
were observed for either baseline or percent change in outcomes.   
Conclusion: SNPs in IL-10 were associated with baseline HOMA-IR. SNPs did not modify the 
association between weight and obesity-associated outcomes. These preliminary findings support 
the notion of genotypic differences in IR for IL-10 gene SNPs, but not the association between 
SNPs and changes in obesity-associated complications resulting from a weight loss intervention. 
More research with a larger sample size is needed to confirm these findings. 
5.2 INTRODUCTION 
Obesity is considered a chronic, low-grade inflammatory disorder, characterized by an 
increase in pro-inflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor 
(TNF)-α, and a decrease in anti-inflammatory cytokines such as adiponectin (AdipoQ) and IL-
10. Insulin resistance (IR), a major contributor to the development of type 2 diabetes, is 
prominent in obesity, and adipose tissue IR contributes to the development of cardiovascular 
disease69. Cytokine levels can thus be considered mediators in the association between obesity 
and the development of IR. Weight loss has been shown to prevent cardiometabolic diseases 
such as IR and improve cytokine function, although results are not conclusive. 
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Several single-nucleotide polymorphisms (SNPs) in cytokine genes have been examined 
in relation to circulating cytokine concentration. SNPs in cytokine genes indicate a 
predisposition to and/or different clinical features or outcomes of IR160. Examples include SNPs 
in IL-6 (rs1800795), TNF-α (rs1800629, rs1800630), AdipoQ (rs1501299, rs266729), and IL-10 
(rs1800896, rs1800871, rs1800872). Evidence from the literature has shown these SNPs to be 
associated with circulating cytokine concentration, but the results have been mixed. Some studies 
have shown a significant association between these variants and circulating cytokine 
concentration26,32,34,181,184,193, while others have not35,180,190,191. Likewise, there are mixed results 
with respect to IR, with an association between cytokine gene SNPs and IR being found in 
some34,170,183,184 but not all171,180,188,202 studies.  
Since obesity is associated with both cytokine expression and IR, it is possible that 
cytokine SNPs and weight interact to affect IR. Yet, few studies have investigated how genotype 
of cytokine SNPs affects IR in response to a weight loss intervention. Given the variability in 
cytokine levels and IR among genetic studies and the limited literature on the effect of genotype 
on IR after weight loss, the purpose of this study is to investigate the interrelationships between 
cytokine SNPs, weight change, and IR among overweight/obese adults enrolled in the SMART 
Trial, a 24-month behavioral weight loss intervention. The goal is to determine whether SNPs in 
IL-6, TNF-α, ADIPOQ, and IL-10 genes influence expression of these cytokines and IR during 
weight loss and regain. 
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5.3 METHODS 
5.3.1 Study Design 
The current study was an ancillary study (K24-NR010742) in which genetic testing of 
candidate cytokine genes were conducted among a subset of participants from the SMART Trial 
(NCT00277771), a single-centered, 24-month clinical trial of behavioral weight loss treatment 
that used a repeated measures design. The recruitment, screening, and enrollment details of the 
SMART Trial are published elsewhere217.  
5.3.2 Study Population 
A total of 65 participants who lost and regained ≥10 lbs of body weight at any time 
during the 24-month study were included in the analysis. Individuals were eligible for inclusion 
in the parent study if they were 18-59 years of age or overweight/obese (BMI 27-43 kg/m2), and 
were excluded if they were heavy (≥4 drinks/day) drinkers; had an eating disorder; or had a 
current serious illness or unstable condition, including a fasting glucose level above 125 mg/dL 
at baseline. All participants provided written informed consent, and the study protocol was 
approved by the University of Pittsburgh Institutional Review Board. 
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5.3.3 Measures 
Body weight and height were measured and a blood sample obtained for assessment of 
total adiponectin, IL-10, IL-6, and TNF-α at baseline, 6, 12, 18, and 24 months. Completion of a 
baseline medical and weight history form provided data for history of an inflammatory illness or 
weight cycling. Sociodemographic data were collected by questionnaire. Energy intake was 
measured in kilocalories per day (kcal/day) by two unannounced 24-hour dietary recalls, 
conducted on one leisure day and one work day.  
5.3.3.1 Anthropometric measures 
Height was measured with a wall-mounted stadiometer and recorded in centimeters. 
Weight and percent body fat were measured following an overnight fast using a Tanita Scale and 
Body Fat Analyzer (Tanita Corporation of America, Inc., Arlington Heights, IL) while 
participants wore light clothing and stood erect with bare feet on the scale’s footpads.  
5.3.3.2 Cytokine measures 
TNF-α was measured by Luminex technology multiplex ELISA (Linco Research, Inc.; 
St. Charles, MO). The minimum detectable level (MDL) was 0.14 pg/mL, with an assay range of 
0.64-10,000 pg/mL. The intra- and inter-assay CVs were 1.4-7.9% and <21%, respectively. A 
quantitative sandwich enzyme immunoassay technique was used to measure IL-6 (Quantiglo 
Human IL-6 Immunoassay; R&D Systems, Minneapolis), with the MDL ranging from 0.05-0.35 
pg/mL and an assay range of 0.48-1500 pg/mL. The intra- and inter-assay CVs were 3.0-5.8% 
and 6.3-9.6%, respectively.  
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IL-10 was measured by quantitative sandwich enzyme immunoassay technique 
(Quantikine HS Human IL-10 Immunoassay; R&D Systems, Minneapolis). The MDL was <0.5 
pg/mL, with an assay range of 0-50 pg/mL. The intra- and inter-assay CVs were 6.6-8.5% and 
8.1-15.6%, respectively. Finally, the ELISA technique was used for the adiponectin assay 
(Quantikine Human Adiponectin/Acrp30 Immunoassay; R&D Systems; Minneapolis), with a 
MDL of 0.25 ng/mL and intra- and inter-assay CVs of 2.5-4.7% and 5.8-6.9%, respectively All 
cytokine assays were performed at the Laboratory for Clinical Biochemistry Research at the 
University of Vermont. 
5.3.3.3 Metabolic measures 
Blood samples were obtained for assessment of insulin and glucose levels, and both 
metabolic measures were analyzed at the University of Pittsburgh Graduate School of Public 
Health’s Chemistry and Nutrition Laboratory. Insulin was measured using a radioimmunoassay 
procedure developed by Linco Research, Inc. Glucose samples were quantitatively determined 
by an enzymatic method described by Bondar and Mead (1974).  The coefficient of variation 
(CV) for insulin was 8.2 +/- 0.7 (170) % and 2.0% for glucose. The intra-assay CVs for insulin 
and glucose were 7.0% and 1.6%, respectively. Insulin resistance was assessed by the 
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated as [fasting insulin 
(μU/mL) x fasting glucose (mg/dL)] / 405.  
5.3.3.4 Genotyping 
DNA was retrieved from whole blood and was extracted by centrifuging the blood, 
removing the white cells, and extracting DNA from the white cells using a simple salting out 
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procedure.  Genotypes were generated using TaqMan allele discrimination with the ABI Prism® 
7000 Sequence Detection System and SDS software version 1.2.3 (Applied Biosystems Inc., 
Carlsbad, CA), using pre-developed and commercially available TaqMan SNP Genotyping 
assays (Applied Biosystems).  Each assay plate contained a negative control, and each SNP was 
genotyped independently by two different individuals and genotype discrepancies were 
addressed by going back to the raw data or re-genotyping. 
5.3.4 Data Analysis 
 Summary statistics for the total sample were reported as either a mean (SD) or frequency 
count (%). All weight, cytokine, and metabolic variables were assessed for normality, and all 
non-normal variables were log-transformed. Hardy-Weinberg equilibrium (HWE) was checked 
for all SNPs with a chi-square test (p≥.05 means SNP was in HWE). The dominant model, where 
carriers of the minor allele were grouped together and compared with homozygous major allele 
carriers, was used due to small numbers.  
Multiple linear regression was used to examine the association between each SNP and 
baseline cytokine concentration or HOMA-IR, adjusting for age, gender, race/ethnicity, and 
baseline weight. Models for HOMA-IR were additionally adjusted for baseline adiponectin and 
TNF-α, which were shown to be significantly associated with HOMA-IR. The interaction 
between baseline weight (as a continuous variable) and each SNP on baseline cytokine levels and 
HOMA-IR was explored; the interaction term was dropped from the model if it was not 
statistically significant. Percent change from baseline to 6, 12, 18 and 24 months was used in the 
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analyses of weight, cytokines, and metabolic measures. Percent change from the study entry time 
point was calculated as [(follow-up – baseline)/ baseline) x 100].  
Linear mixed modeling with linear contrasts was applied to assess the effects of SNPs on 
changes in cytokines and HOMA-IR from baseline. Models included time, age, race, gender, 
baseline cytokine or HOMA-IR, baseline weight, percent weight change, and an interaction term 
for each SNP x percent weight change. The interaction term was also dropped from the model if 
it was not statistically significant. In each model, a random intercept was used for each 
participant, and an unstructured covariance structure was assumed. P-values from the F-tests 
were reported.  In all analyses, the significance level was set at p<0.05 for two-sided hypothesis 
testing. Analyses of the data were conducted using SAS version 9.2 (SAS Institute, Cary, NC) 
and IBM SPSS Statistics version 21.0 (IBM Corporation, Armonk, NY). 
5.4 RESULTS 
Baseline demographic and clinical characteristics for participants are shown in Table 1. 
The sample was predominately female (80%), White (88%), and middle-aged (48.7±6.9 years). 
The mean BMI of the sample was 34.6±kg/m2 and mean body fat composition was 42.1±6.1%. 
Mean baseline glucose was 96.5±8.9 mg/dL and mean insulin was 16.9±6.0 µU/mL. Overall, 
there was an 11% decrease in weight, a 13.7% increase in adiponectin, an 8.6% decrease in 
insulin, and a 9.2% decrease in HOMA-IR at 6 months (ps<.05). By 24 months, only adiponectin 
concentration significantly decreased with nearly total weight regain. SNP characteristics, 
including the minor allele frequency (MAF) are presented in Table 2 for IL-6, TNF-α, ADIPOQ, 
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and IL-10. These genes were selected based on the role of these cytokines in obesity and obesity-
associated health outcomes. Although 65 participants were genotyped for at least one SNP, not 
all participants were able to be genotyped for all eight SNPs; therefore, there was variability in 
the number of participants within each genotype group. All SNPs were in HWE. 
Table 3 outlines the association between each SNP and cytokine concentration, 
controlling for age, ethnicity, gender, and body weight. Overall, genotype was not significantly 
associated with baseline cytokine concentration. The association between genotype and HOMA-
IR, controlling for age, ethnicity, gender, baseline body weight, baseline adiponectin, and 
baseline TNF-α are outlined in Table 4. Overall, IL-10 SNPs rs1800896, rs1800871, and 
rs1800872 were significantly associated with HOMA-IR (ps<.05). Compared to individuals with 
the TT genotype, variant C allele carriers of rs1800896 had higher HOMA-IR [b(se)=1.0 (0.4), 
p=.02]. Compared with individuals homozygous for the major allele, minor allele carriers for 
rs1800871 and rs1800872, respectively, had lower HOMA-IR [for both SNPs: b(se)=-1.2 (0.4), 
p=.01]. Results of the linear mixed models, adjusting for covariates, are outlined in Tables 5 and 
6. Overall, there were no significant associations between genotype and outcomes over time. 
There was, however, a significant within-group difference in percent change in HOMA-IR for 
rs1800872. Individuals with the GG genotype significantly decreased HOMA-IR by 6.0% 
(p=.02), whereas T allele carriers did not (-1.0%, p=.31). 
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5.5 DISCUSSION 
These preliminary results reveal, in a sample of obese adults who lost and regained at 
least 10 lbs as part of a behavioral weight loss study, significant associations between SNPs in 
the IL-10 gene and baseline HOMA-IR. However, we did not observe any significant 
associations between genotype and baseline cytokine concentration, or genotype and percent 
changes in cytokines or HOMA-IR over time.  
At baseline, we observed minor allele carriers of IL-10 rs1800896 to have significantly 
higher HOMA-IR compared to individuals with the TT genotype. We also found carriers of the 
variant A and T alleles of IL-10 rs1800871 and rs1800872, respectively, to have lower HOMA-
IR, compared with individuals homozygous for the major allele. These IL-10 SNPs have been 
researched in the context of diseases such as asthma231, gastric cancer232, and Crohn’s disease201. 
However, the association between these SNPs and obesity-associated complications is limited in 
the literature. To our knowledge, no studies have investigated the associations between 
rs1800871 and IR, and only one other study investigated the association between rs1800896, 
rs1800871 and IR. Scarpelli et al. examined the association between rs1800896, rs1800872 and 
HOMA-IR among non-diabetic obese Caucasian adults. They found that carriers of the minor 
allele had higher HOMA-IR compared to individuals homozygous for the major allele, but did 
not find an association between rs1800896 and HOMA-IR34. This is in contrast to our study 
where we found minor allele carriers of rs1800896 and rs1800872 to have higher and lower, 
respectively, HOMA-IR compared to carriers of the homozygous wild genotype.  
It is difficult to explain why the results of the current study are in contrast to those of 
Scarpelli et al. The differences between the two studies could be due to differences in sample 
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size and ethnic origin of the populations. The global minor allele frequencies for the IL-10 SNPs 
are different between racial/ethnic groups. Scarpelli et al. had a more homogeneous population, 
whereas our sample population was less homogeneous; we included eight individuals who were 
of non-Caucasian descent. However, when analyzing the data with Caucasians only, the results 
were similar. Therefore, there could be three explanations for disparate findings. First, these 
SNPs have not been well-researched in the context of IR; therefore, the alleles for rs1800896 and 
rs1800872 that would be considered the risk allele for IR is inconclusive. Second, Caucasians in 
the U.S. may not represent a homogeneous population; varying ancestry within U.S. Caucasian 
populations may explain our results. Lastly, contrasting results may simply be due to different 
sample sizes. The current study included 65 individuals, whereas Scarpelli et al. included over 
1100 non-diabetic obese individuals.  Therefore, more clarification on the association between 
IL-10 expression and obesity-associated health outcomes is needed, in addition to more research 
with larger sample sizes on the role of IL-10 SNPs in obesity and metabolic diseases.    
We did not observe significant associations between SNP and percent change in 
cytokines or HOMA-IR over time. The associations between weight change, cytokine gene SNP, 
and IR is understudied in the literature. Curti et al. investigated the association between cytokine 
gene SNPs and cardiometabolic risk factors such as IR among obese Brazilian adults who 
participated in a lifestyle intervention, emphasizing a healthy diet, increased physical activity, 
and psychosocial stress management40. They found improvements in cytokines and insulin 
concentration (IR was not assessed) after the intervention in both genotype groups for each SNP. 
However, they did not investigate the association between IL-10 SNPs and outcomes, nor did 
they explore the interaction between intervention changes (e.g. weight change) and SNPs on 
certain outcomes. They also only adjusted for age and gender, and may have biased results due to 
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lack of adjustment for other variables associated with their outcomes, such as baseline weight. 
Lastly, as with our study, they had a small sample size. Studies incorporating larger sample sizes 
are needed to confirm these findings.  
Although we did not find any significant between-group differences in percent change in 
outcomes over time, we did observe significant within-group differences in HOMA-IR from 
baseline to 24 months for individuals with the GG genotype for rs1800872. Those with the GG 
genotype had significantly higher baseline HOMA-IR compared to T allele carriers; however, 
unlike T allele carriers, they had a significant decrease in HOMA-IR over time. This suggests 
that individuals with the GG genotype or individuals with higher baseline HOMA-IR may have 
greater improvement in metabolic outcomes following a weight loss intervention. Additional 
research is needed to determine differences in metabolic responses to weight loss.  
There are some limitations to this study. First, we had a small sample size, thus giving a 
low power to detect associations between genotype and outcomes. However, these data are 
exploratory, and we believe that the findings are informative and may pave the way for the 
analysis of these associations in larger studies. Second, we cannot rule out the possibility of 
linkage disequilibrium between SNPs in the current study and SNPs that have yet to be 
discovered. Strengths of the study are that we examined SNPs in genes known to be associated 
with obesity and IR, and that there is a lack of information on these SNPs in relation to IR among 
obese adults enrolled in a weight loss study. Our sample population was unique; we included 
individuals who lost and regained ≥ 10 lbs during the weight loss study and included 
measurements at multiple time points, thus allowing us to determine the association of cytokine 
SNPs and longitudinal changes in our outcomes. We also investigated multiple SNPs in cytokine 
genes to give a more comprehensive view of the association between these SNPs and outcomes.  
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Future studies need to investigate the role that weight loss and regain play on the 
association between cytokine SNPs and obesity-associated complications such as inflammation 
and IR. Given the lack of attention in the literature to IL-10 expression in obesity and IR, more 
research is needed to clarify the role of this anti-inflammatory cytokine in obesity-associated 
complications to obtain a better understanding of how IL-10 SNPs are associated with health 
outcomes. Future research should also include the investigation of haplotypes, which can provide 
more information on the association between genetic variants and disease. More research is also 
needed on the association between these SNPs and outcomes among individuals who are most at 
risk for obesity and IR, such as minority populations and individuals of a lower socioeconomic 
status. In addition, it is necessary to explore gene-gene interactions, and interactions between 
cytokine genes and environmental factors such as diet and physical activity.   
In conclusion, SNPs in IL-10 genes were significantly associated with IR. There were no 
associations between SNPs and changes in cytokines or IR over time. These preliminary findings 
suggest that there may be allelic differences in IL-10 SNPs in terms of IR; however, more 
research with a larger sample is needed to confirm these results.  
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Table 5-1 Baseline demographic and clinical characteristics of the participants (N=65) 
 
Characteristic 
 
n (%) 
Gender 
     Female 
 
52 (80.0) 
Race 
      
     White 
 
 
57 (87.7) 
  
Mean (SD) 
Age (years) 48.7 (6.9) 
Weight (kg) 97.0 (15.4) 
Waist circumference (cm) 
     Female 
     Male 
 
105.4 (12.1) 
119.3 (11.4) 
Body Fat Composition (%) 42.1 (6.1) 
BMI (kg/m2) 34.6 (4.3) 
Adiponectin (µg/mL) 17.0 (9.2) 
IL-6 (pg/mL) 2.6 (1.5) 
IL-10 (pg/mL) 8.6 (4.0) 
TNF-α (pg/mL) 5.1 (4.4) 
Glucose (mg/dL) 96.5 (8.9) 
Insulin (µU/mL) 16.9 (6.0) 
HOMA-IR 4.1 (1.7) 
sd, standard deviation; kg, kilograms; cm, centimeters; kg/m2, kilograms/meters squared; µg/mL, 
micrograms/milliliter; pg/mL, pictograms/milliliter 
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Table 5-2 Description of cytokine polymorphisms 
 
Chromosome 
(Position) 
 
 
Gene 
 
 
SNP 
 
Major 
Allele 
 
Minor 
Allele 
 
 
MAFa 
 
Global 
MAFb 
3q27 (+216) ADIPOQ rs1501299 G T 0.34 0.32 
3q27 (-11377) ADIPOQ rs266729 C G 0.16 0.29 
7p21 (-174) IL-6 rs1800795 G C 0.31 0.50 
1q31-32 (-1082) IL-10 rs1800896 T C 0.47 0.47 
1q31-32 (-819) IL-10 rs1800871 G A 0.29 0.47 
1q31-32 (-592) IL-10 rs1800872 G T 0.28 0.24 
6p21 (-308) TNF-α rs1800629 G A 0.13 0.17 
6p21 (-863) TNF-α rs1800630 C A 0.15 0.16 
aMinor allele frequency 
bMAF for global Caucasian population from the Single Nucleotide Polymorphism Database, 
National Center for Biotechnology Information/National Human Genome Research Institute 
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Table 5-3 Associations between SNPs and baseline cytokine concentrationa,b 
 
SNP 
 
Gene 
 
βc 
 
SEd 
 
P 
rs1501299 ADIPOQ -0.1 0.1 0.16 
rs266729 ADIPOQ -0.03 0.1 0.64 
rs1800795 IL-6 -0.04 0.04 0.27 
rs1800896 IL-10 -0.02 0.05 0.71 
rs1800871 IL-10 -0.004 0.05 0.93 
rs1800872 IL-10 0.001 0.05 0.98 
rs1800629 TNF-α -0.03 0.06 0.60 
rs1800630 TNF-α 0.06 0.06 0.31 
aMultiple linear regression models, adjusting for age, race/ethnicity, gender, and baseline weight 
bLog-transformed cytokine concentration 
cregression coefficient 
dstandard error 
Referent group is carriers of the variant allele 
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Table 5-4 Associations between SNPs and baseline HOMA-IR 
 
SNP/Gene 
 
βa 
 
SEb 
 
P 
rs1501299 0.03 0.03 0.38 
rs266729 -0.02 0.03 0.62 
rs1800795 -0.03 0.03 0.29 
rs1800896 1.0 0.4 0.02 
rs1800871 -1.2 0.4 0.01 
rs1800872 -1.2 0.4 0.01 
rs1800629 -0.02 0.03 0.60 
rs1800630 0.03 0.03 0.38 
aRegression coefficients, controlling for age, ethnicity, gender, baseline weight, baseline log-
transformed adiponectin, baseline log-transformed TNF-α 
bStandard error 
Referent group is carriers of the variant allele 
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Table 5-5 Linear mixed modeling of associations between variants and percent change in 
cytokines over timea,b,c 
 
SNP 
 
Gene 
 
β 
 
SE 
 
P 
rs1501299 ADIPOQ -5.5 5.2 0.34 
rs266729 ADIPOQ 2.3 5.7 0.58 
rs1800795 IL-6 2.4 7.1 0.83 
rs1800896 IL-10 -1.0 9.3 0.96 
rs1800871 IL-10 -2.1 9.0 0.98 
rs1800872 IL-10 5.9 7.7 0.36 
rs1800629 TNF-α -2.2 8.7 0.64 
rs1800630 TNF-α 1.2 8.7 0.49 
aModels include time, age, ethnicity, gender, baseline weight, and respective baseline log-
transformed cytokine concentration 
bCytokine corresponding to the gene 
cPercent change in log-transformed cytokine 
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Table 5-6 Linear mixed modeling of associations between variants and percent change in 
HOMA-IR over timea 
 
SNP 
 
Gene 
 
β 
 
SE 
 
P 
rs1501299 ADIPOQ -4.2 4.7 0.23 
rs266729 ADIPOQ 4.8 5.0 0.42 
rs1800795 IL-6 -3.7 5.0 0.37 
rs1800896 IL-10 -2.0 5.4 0.59 
rs1800871 IL-10 -6.7 5.1 0.22 
rs1800872 IL-10 -5.0 5.1 0.36 
rs1800629 TNF-α -2.5 5.2 0.51 
rs1800630 TNF-α -0.3 5.5 0.82 
aModels include time, age, ethnicity, gender, baseline weight, baseline log-transformed 
adiponectin, baseline log-transformed TNF-α 
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6.0  DISSERTATION SUMMARY 
6.1 OVERALL SUMMARY 
 This dissertation examined the association between weight loss and regain, cytokine 
concentration, and insulin resistance among overweight/obese adults enrolled in the SMART 
Trial, a 24-month clinical trial of treatment for weight loss. In the first study, we found that 
moderate (11%) 6-month weight loss was associated with significant improvements in 
adiponectin and IL-6, but not IL-10 and TNF-α. We also found that, with nearly total weight 
regain, adiponectin was higher and IL-6 was lower than baseline, suggesting that moderate 
weight loss produced a lagged effect for these cytokines. Although 24-month values were better 
than baseline, there was some attenuation in cytokines at the end of the study. It may be that the 
benefits of weight loss on cytokines last for a certain amount of time, although this amount has 
not been determined in the literature. It is also possible that the amount of weight that is regained 
determines the course of cytokine expression. Nevertheless, from these results, it is clear that 
weight loss improves inflammation despite weight regain. 
In the second study, we found that weight loss was associated with improvements in 
insulin concentration and HOMA-IR. However, despite our findings of a lagged effect for 
cytokines during a period of weight regain, we found that insulin concentration and HOMA-IR at 
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24 months surpassed baseline values. The literature has shown that insulin sensitivity that occurs 
after intentional weight loss is a predictor of subsequent weight regain, and that degree of weight 
regain after weight loss is dependent upon changes in insulin sensitivity as well as adherence to 
fat, calorie, and exercise goals from the weight loss intervention233. The increased insulin and 
HOMA-IR at 24 months beyond baseline values may reflect a decline in adherence to fat and 
calorie goals. Although we did observe higher levels of insulin and HOMA-IR at 24 months 
compared to baseline, these results were not statistically significant. It may be that improvement 
in metabolic measures was most noticeable during the period of weight loss rather than regain, 
suggesting that weight loss may be more important than regain in affecting insulin and HOMA-
IR. There may be variability among individuals in insulin response to changes in body weight, 
especially among individuals of normal glucose tolerance234. It also may be that there is more 
variability in insulin response to regain compared to the weight loss period. Long-term changes 
in insulin action and secretion in weight regain is unclear.  
The third paper was an ancillary study (K24-NR010742) in which genetic testing of 
candidate cytokine genes were conducted among participants from the SMART Trial. We 
examined the association between cytokine SNPs and cytokine concentration and insulin 
resistance. We found that SNPs in the IL-10 gene were associated with baseline HOMA-IR. 
Specifically, the variant C allele for rs1800896 was associated with higher HOMA-IR compared 
to the TT genotype. We also found carriers of the variant alleles for rs1800871 and rs1800872 to 
have lower HOMA-IR compared to carriers of the homozygous wild genotype. We did not 
observe an association between other SNPs and cytokine levels or HOMA-IR, nor did we 
observe any associations between SNPs and percent changes in outcomes over time. However, 
we did find that individuals with the GG genotype for rs1800872 had a decrease in HOMA-IR 
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over time, despite having a higher HOMA-IR at baseline than T allele carriers. These findings 
suggest that genotype may play a role in IR. Also, although our results do not show any 
significant between-group differences in percent change in outcomes over time, we did observe a 
within-group difference in percent change in HOMA-IR over time for GG genotype carriers. 
This suggests improvement in IR during a weight loss intervention among individuals with the 
GG genotype. The literature is limited on the associations between cytokine gene SNPs and 
obesity-associated complications. There is much variability in these associations, with some 
studies finding cytokine gene SNPs to be associated with obesity-associated outcomes, whereas 
other studies have not. Only one study investigated IL-10 SNPs in relation to metabolic 
outcomes34, and these results were in direct contrast to our results. It may be that our sample size 
is too small to detect meaningful differences, or variability in results might be explained by 
differences in ethnic origin of the populations. It is also possible that, because this SNP has not 
been well-researched in the context of IR, the association between risk alleles for IL-10 SNPs is 
inconclusive.  
In summary, these three studies highlight the complex nature of obesity and weight 
change in relation to obesity-associated complications such as inflammation and metabolic 
outcomes. We revealed that weight loss was significantly associated with improvements in both 
cytokines and IR, but that these improvements were not sustained during a period of weight 
regain. This highlights the need for developing strategies to promote weight maintenance in the 
prevention of cardiometabolic diseases. We also highlighted the role of cytokine genes SNPs in 
IR, particularly in the IL-10 gene.  
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6.2 LIMITATIONS 
There are certain limitations that need to be addressed. We did not have a control 
group with which to compare our results. Although we found significant associations, we 
cannot make any causal inference. Male representation in the study was low; however, 
our sample was representative of those who typically seek treatment for weight loss. IR 
was measured by HOMA-IR, a surrogate marker derived from a mathematical 
model, rather than the hyperinsulinemic euglycemic clamp, which is considered the gold 
standard for measuring IR. However, HOMA-IR has been well-validated when compared 
with the gold standard. For the SNP analysis, we had a small number of individuals, thus 
giving a lower power to detect meaningful differences. There may also be issues with 
linkage disequilibrium between the SNPs used in this study and unknown SNPs. Finally, our 
sample population was healthy with specific ages and BMIs, thus limiting generalizability to 
other populations.  
6.3 PUBLIC HEALTH SIGNIFICANCE 
 Obesity has reached epidemic proportions in the U.S. with over one-third of 
Americans being obese1. Concurrent with the growing obesity epidemic is the increase in 
type 2 diabetes and cardiovascular disease, both major causes of morbidity and mortality. 
The findings from this dissertation reveal that changing behaviors such as reducing energy 
intake and increasing energy expenditure, which lead to weight loss, can improve 
cardiometabolic outcomes and reduce inflammation. However, it is difficult to maintain 
weight, and weight regain can have a detrimental effect on one's health. Therefore, it
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is necessary to devise strategies to prevent weight regain, thus reducing the risk of developing 
cardiometabolic diseases.   
Obesity is a complex disorder, which includes the interaction between behavioral, 
environmental, and genetic factors. Cytokine gene polymorphisms can be informative in 
determining risk for IR and how an individual responds to a weight loss intervention. This 
dissertation revealed that individuals who were carriers of a particular allele had greater IR 
compared to individuals of the alternative allele. Tailoring weight loss interventions to specific 
genotypes may lead to an improved risk profile in those most susceptible to diabetes. 
6.4 FUTURE RESEARCH 
Future research needs to examine the associations between changes in 
adiposity and cardiometabolic risk factors such as inflammation and IR using advanced 
methods of adiposity detection, e.g. magnetic resonance imaging or computerized tomography. 
Visceral adipose tissue is known to be a greater risk factor for inflammation and 
cardiometabolic disease compared with subcutaneous adipose tissue88, and advanced methods 
for measuring this depot may give insight into the association between adiposity and 
cardiometabolic risk factors. Subclinical measures of cardiovascular disease, such as pulse-
wave velocity and coronary artery calcification, should be investigated in association with 
weight change, cytokine concentration, and cytokine gene polymorphisms. Future studies 
need to focus on increasing male participation in weight loss interventions. Findings from 
this dissertation revealed that males have higher insulin and adiponectin concentrations 
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at baseline compared with females, and a significant interaction between gender and 
percent change in weight on percent change in adiponectin over time revealed that males 
had a higher increase in adiponectin with weight loss compared with females. This 
suggests highlights a potential health benefit of weight loss, particularly for males, who may be 
at an increased risk of developing cardiometabolic diseases. 
Inflammation is a hallmark of obesity and is implicated in the development of 
cardiometabolic diseases such as IR. Anti-inflammatory markers such as adiponectin have been 
well-researched in the literature in relation to obesity and IR. However, other anti-inflammatory 
markers such as IL-10 are very informative, but not well-researched. Therefore, there needs to be 
a greater understanding of the role of anti-inflammatory cytokines beyond adiponectin on health 
outcomes, and the effects of weight loss and regain on expression of these cytokines.  
Although the SMART Trial was a 24-month clinical trial, and most weight loss studies 
are short-term (6 months or less), studies with longer follow-up are needed to determine the 
effects of weight regain on cytokines and IR. It is necessary to examine differences between 
individuals who lost and regained weight, those who lost and maintained weight, individuals 
who maintained obesity, and normal weight individuals, to decipher the role of weight cycling on 
health outcomes. More studies are needed examining these associations among populations who 
are known to have higher obesity and cardiometabolic disease, such as African-Americans235. 
For the investigation of cytokine gene SNPs and IR, future research should include larger 
sample sizes with enough power to detect differences. Because obesity is a disorder that is a 
combination of genetic, behavioral, and environmental factors, studies should explore gene-gene 
interactions, as well as gene-diet, gene-BMI, and gene-physical activity interactions. Haplotype 
analyses, which could potentially provide more relevant information, should also be conducted. 
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Studies should include genetic analysis among sociodemographic and racial/ethnic groups at risk 
for obesity-associated complications. This study included individuals of all racial/ethnic groups, 
although the majority of the participants were Caucasian. Race/ethnicity was controlled for in all 
models; however, this is not a very robust method for genetic analysis due to differences in allele 
frequencies between racial/ethnic groups. Therefore, the data were re-analyzed among 
Caucasians only, and the results were unchanged. This may hint at the lack of homogeneity 
among Caucasians in the U.S. A more robust method in genetic analysis to control for population 
substructure is the use of ancestry informative markers (AIMs). AIMs are markers not associated 
with disease that reflect a quantitative measurement of an individual’s ancestry. Thus, controlling 
for AIMs in studies among non-homogeneous populations can be more accurate than controlling 
for self-reported race/ethnicity, and can account for variability in ancestry among individuals of 
the same race. The implementation of these methods to examine ancestral differences is critical 
in determining genetic associations among individuals with substantial admixture between 
continents236. 
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APPENDIX 
                                             SMART TRIAL CONSORT DIAGRAM 
 
 
 
 
 
 
  
Randomly Assigned (n = 210) 
Assessed for eligibility by phone (n = 704) 
PDA+FB group 
(n = 70) 
PDA group 
(n = 68) 
PD group 
(n = 72) 
Completed 6-month 
assessment  
n = 65, 92.9% 
Completed 6-month 
assessment  
n = 64, 94.1% 
 
Completed 6-month 
assessment  
n = 63, 87.5% 
Completed 12-month 
assessment  
n = 60, 85.7% 
 
Completed 12-month 
assessment  
n = 60, 83.3% 
Completed 12-month 
assessment  
n = 60, 88.2% 
 
Completed 18-month 
assessment  
n = 58, 82.9% 
 
Completed 18-month 
assessment  
n = 58, 85.3% 
 
Completed 18-month 
assessment  
n = 61, 84.7% 
Completed 24-month 
assessment  
n = 59, 84.3% 
 
Completed 24-month 
assessment  
n = 59, 86.8% 
 
Completed 24-month 
assessment  
n = 62, 86.1% 
Discontinued study 
participation (n = 11): 
• Lost to follow-up (n = 9)
• Pregnancy (n = 1)
• Withdrawal (n = 1)
 
Discontinued study 
participation (n = 9): 
• Lost to follow-up (n =7)
• Pregnancy (n = 2)
Discontinued study 
participation (n = 10): 
• Lost to follow-up (n =8)
• Withdrawal (n = 2)
494 excluded 
263 did not meet eligibility 
criteria 
198 declined to participate 
33 other reasons 
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